healthevidencedigest

Blog

  • AML in Older Adults Has Been Treated With IV Infusions for Years. The FDA Just Approved the First All-Oral Alternative.

    AML in Older Adults Has Been Treated With IV Infusions for Years. The FDA Just Approved the First All-Oral Alternative.

    📌 The essentials On May 13, 2026, the FDA approved Inqovi (decitabine and cedazuridine, Taiho Oncology) in combination with venetoclax for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy. This is Inqovi’s third FDA-approved indication, joining myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), both approved in 2020. What makes it first-in-class: Inqovi plus venetoclax is the first and only all-oral hypomethylating agent (HMA) plus BCL-2 inhibitor combination approved in any cancer setting. The previous standard of care for this population, azacitidine plus venetoclax (Venclexta), requires intravenous or subcutaneous azacitidine injections. The clinical basis: Phase 2b ASCERTAIN-V trial (NCT04657081), 101 adults with newly diagnosed AML ineligible for intensive chemotherapy. CR rate: 46.5% (95% CI 36.5 to 56.7%). CR/CRi rate: 63.4%. Median time to CR: 2.4 months. 75.3% of CR patients maintained remission at 12 months. Median OS: 15.5 months (95% CI 7.6 to not estimable). Safety: Grade 3 or higher adverse events in 98% of patients, consistent with known HMA/BCL-2 inhibitor class profile; febrile neutropenia, anemia, and neutropenia most frequent; no new drug-drug interaction signals. Dosing: Inqovi (35 mg decitabine / 100 mg cedazuridine) orally on days 1 to 5 of each 28-day cycle, with venetoclax 400 mg daily after cycle 1 ramp-up. All oral. No clinic infusion required.

    Acute myeloid leukemia is among the most challenging blood cancers to treat. It is diagnosed in an estimated 22,720 Americans in 2026, and it has an uncomfortable demographic reality: it predominantly affects older adults, with a median diagnosis age of approximately 68 years. The same patients who are most likely to develop AML are often the least able to tolerate the treatment that offers the best chance of remission, intensive induction chemotherapy involving days of hospitalization, profound bone marrow suppression, and significant mortality risk even when the treatment works.

    For older adults and those with significant comorbidities, the established approach over the past five years has been a less intensive regimen of azacitidine or decitabine, both given by injection or infusion, combined with venetoclax (Venclexta, AbbVie/Genentech), an oral BCL-2 inhibitor. This HMA/BCL-2 combination transformed the treatment landscape for “unfit” AML patients after the pivotal VIALE-A trial, establishing remission rates and survival outcomes that were meaningfully better than HMA alone.

    The problem is the parenteral component. Azacitidine requires injections or infusions on 7 days of every 28-day cycle, meaning patients must come to a clinic or have a home health nurse administer the drug regularly throughout treatment. For a 78-year-old with heart failure, limited mobility, or inadequate transport, this creates a real and sometimes insurmountable access barrier.

    On May 13, 2026, the FDA approved a solution to that access problem: Inqovi (decitabine and cedazuridine) plus venetoclax, an all-oral alternative that achieves equivalent drug exposure to intravenous decitabine through a pharmacological workaround, administered entirely at home.

    What Inqovi Is and the Problem It Was Designed to Solve

    Inqovi is a fixed-dose combination tablet containing two drugs: decitabine and cedazuridine. Understanding why both are needed together requires understanding why oral decitabine alone does not work.

    Decitabine: the hypomethylating agent

    Decitabine is a nucleoside analog that works as a DNA hypomethylating agent (HMA). In cancer cells, abnormal DNA methylation silences tumor suppressor genes that would otherwise limit malignant growth. Decitabine incorporates into DNA and inhibits DNA methyltransferase (DNMT), reversing this silencing and restoring normal gene expression patterns. It is a well-established and effective anti-leukemia mechanism.

    The problem is delivery. Decitabine taken orally is rapidly broken down in the gut and liver by an enzyme called cytidine deaminase (CDA) before it can reach the bloodstream in therapeutic concentrations. This is why intravenous decitabine and subcutaneous azacitidine have been used for decades: bypassing the gastrointestinal route avoids this degradation.

    Cedazuridine: the CDA inhibitor that makes oral delivery work

    Cedazuridine is a selective inhibitor of cytidine deaminase in the gut and liver. When cedazuridine is co-administered with decitabine, it blocks the enzyme responsible for degrading decitabine in the gastrointestinal tract, allowing therapeutic concentrations of decitabine to be absorbed and to reach systemic circulation.

    Pharmacokinetic studies comparing oral Inqovi to IV decitabine 20 mg/m² demonstrated bioequivalent systemic exposure. The AUC (area under the concentration-time curve) for decitabine given as Inqovi matches IV decitabine, which was the key regulatory and clinical evidence establishing that the pill delivers the same drug at the same concentration as the infusion. This equivalence was demonstrated in the pivotal ASCERTAIN trial that supported Inqovi’s original 2020 approval for MDS and CMML.

    Venetoclax: the BCL-2 inhibitor that completes the combination

    Venetoclax (Venclexta) is an oral BCL-2 inhibitor that works through a completely distinct mechanism: it blocks the BCL-2 protein, which cancer cells overexpress to prevent their own programmed death (apoptosis). By blocking BCL-2, venetoclax restores the apoptotic pathway, causing AML cells to die. The synergy between HMA and BCL-2 inhibition is well-established: HMA therapy primes AML cells toward apoptosis, and venetoclax completes the process.

    Venetoclax has been oral since its approval. The barrier to an all-oral HMA/BCL-2 regimen was always the parenteral HMA component. Inqovi resolves that barrier.

    Why “all-oral” matters clinically beyond convenience The shift from intravenous azacitidine to oral Inqovi is not merely a quality-of-life upgrade, though quality of life matters significantly in older patients with AML. It has tangible clinical implications. Parenteral HMA regimens require 7 treatment days per cycle for azacitidine, meaning patients must arrange transportation to a clinic or home health services 7 times per month, often indefinitely. For a patient who lives alone, relies on others for transportation, or has mobility limitations from heart failure, pulmonary disease, or peripheral neuropathy, these logistical demands create real discontinuation risk. Studies in AML and MDS have documented that patients on parenteral HMA regimens miss doses or discontinue treatment earlier than protocol intent due to the burden of frequent clinic visits. An oral regimen administered at home on days 1 to 5 of a 28-day cycle eliminates these specific barriers entirely.

    AML in Patients Ineligible for Intensive Chemotherapy: Who Is This Population?

    The FDA-approved indication covers adults aged 75 or older, or adults with comorbidities that preclude intensive induction chemotherapy. This population has specific characteristics that make treatment selection different from younger, fit patients.

    Intensive induction chemotherapy for AML, typically the “7+3” regimen of cytarabine and anthracycline, is effective but produces profound myelosuppression (bone marrow suppression) and requires weeks of inpatient hospitalization. Early mortality rates with intensive therapy approach 10 to 15% in older patients, largely from infections and organ toxicity during the aplastic period. For a patient aged 75 with renal insufficiency, uncontrolled heart failure, or severe pulmonary disease, the risk of dying from the treatment may exceed the benefit.

    The ASCERTAIN-V trial population reflects this clinical reality: median age was 78 years, 51.5% had ECOG performance status of 1, and 16.8% had TP53 mutations (associated with particularly poor prognosis). The distribution across European LeukemiaNet (ELN) risk categories was: favorable 31.7%, intermediate 33.7%, adverse 29.7%, reflecting a realistic mix of disease risk rather than a cherry-picked low-risk population.

    The ASCERTAIN-V Trial: Full Results

    Design

    ASCERTAIN-V (NCT04657081) is an international, multicenter, open-label, single-arm, Phase 2 study. The Phase 2b portion enrolled 101 adults with newly diagnosed AML per WHO 2016 criteria, ECOG performance status 0 to 3, ineligible for intensive induction chemotherapy, with a life expectancy of at least 3 months.

    Dosing schedule per 28-day cycle:

    • Cycle 1 (venetoclax ramp-up): venetoclax 100 mg day 1, 200 mg day 2, 400 mg day 3 through day 28; Inqovi days 1 to 5
    • Cycle 2 onward: Inqovi days 1 to 5; venetoclax 400 mg daily

    Median follow-up at time of analysis: 11.2 months.

    Efficacy results

    OutcomeResult
    Complete remission (CR) rate46.5% (95% CI 36.5 to 56.7%)
    CR plus CRi (incomplete hematologic recovery) rate63.4% (95% CI 53.2 to 72.7%)
    CR plus CRh (partial hematologic recovery) rate51.5% (95% CI 41.3 to 61.6%)
    Median time to CR2.4 months
    Patients in CR at 6 months80.0%
    Patients in CR at 12 months75.3%
    Median duration of CRNot reached at time of analysis
    Median overall survival15.5 months (95% CI 7.6 to not estimable)

    Source: ASCERTAIN-V Phase 2b results. Presented at ASCO 2025 Annual Meeting and EHA Congress 2025. Taiho Oncology press release, May 13, 2026. NCT04657081.

    Contextualization against the standard of care

    The obvious benchmark is the VIALE-A trial, which established azacitidine plus venetoclax as the standard for unfit AML. VIALE-A produced a CR rate of 24.2% and a median OS of 14.7 months in the venetoclax arm. The ASCERTAIN-V CR rate of 46.5% and median OS of 15.5 months are directionally favorable, though cross-trial comparison must be interpreted with caution given differences in patient selection, trial design, and follow-up periods.

    Why cross-trial comparisons must be interpreted cautiously ASCERTAIN-V and VIALE-A enrolled patients using different criteria, at different time periods, in different geographic mixes of sites. ASCERTAIN-V’s single-arm design without a comparator arm means there is no concurrent control to account for evolving supportive care standards, referral patterns, or patient selection over time. The CR rates may also reflect different definitions or measurement timing. The appropriate conclusion from ASCERTAIN-V is that the all-oral combination achieves remission and survival outcomes consistent with published HMA/venetoclax benchmarks in this population, not that it is proven superior to azacitidine/venetoclax. A randomized confirmatory trial comparing the two approaches directly would be needed to establish superiority.

    Safety results

    Safety results from ASCERTAIN-V were consistent with the known profiles of both drugs in this class and in this patient population. These are not mild side effects: AML patients treated with HMA/BCL-2 inhibitor combinations experience significant myelosuppression, and the grade 3 or higher adverse event rate reflects this.

    Safety outcomeRate
    Grade 3 or higher adverse events (any)98.0% of patients
    Febrile neutropeniaMost common grade 3 or higher event
    Anemia (grade 3 or higher)Frequent
    Neutropenia (grade 3 or higher)Frequent
    Dose interruptions68.3%
    Discontinuations due to adverse events8.9%
    Fatal adverse events15.8% (3 attributed to adverse events, 10 to disease progression per 30/60-day mortality assessment)
    New drug-drug interactions (venetoclax/decitabine)None identified

    The 98% grade 3 or higher adverse event rate is alarming on first read but is consistent with what hematologists and patients should expect in AML treatment. Myelosuppression is inherent to HMA therapy in a disease characterized by dysfunctional bone marrow. The absence of new drug-drug interaction signals between oral decitabine and venetoclax (which was a theoretical concern given cedazuridine’s CDA inhibition affecting venetoclax metabolism) is an important safety finding.

    Venetoclax requires co-administration with a CYP3A4 inhibitor prophylaxis protocol during ramp-up. Patients on antifungal prophylaxis (such as posaconazole or fluconazole) need venetoclax dose reductions during ramp-up because these agents inhibit CYP3A4 and increase venetoclax exposure. Prescribers managing this combination must follow the venetoclax drug interaction tables carefully.

    Safety Warnings: What the Label Covers

    The Inqovi prescribing information includes important safety warnings that apply to the AML indication:

    Myelosuppression: Inqovi can cause severe myelosuppression in patients with AML, including fatal adverse reactions. Complete blood count monitoring before each treatment cycle and as clinically indicated is required.

    Differentiation syndrome: HMA agents and venetoclax can cause differentiation syndrome in AML, a potentially life-threatening inflammatory reaction caused by rapid differentiation of leukemic cells. Symptoms include fever, dyspnea, hypoxemia, rapid weight gain, and pleural or pericardial effusion. This is a medical emergency requiring corticosteroids and sometimes treatment interruption.

    Embryo-fetal toxicity: Inqovi can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. Breastfeeding should not occur during treatment and for at least 2 weeks after the final dose.

    Interactions with venetoclax: Strong or moderate CYP3A4 inhibitors increase venetoclax exposure and require dose adjustments. Avoid strong CYP3A4 inducers. The full venetoclax prescribing information and dose modification tables for drug interactions apply throughout the regimen.

    Dosing: The All-Oral Treatment Schedule

    The ASCERTAIN-V-based treatment schedule is:

    Cycle 1 (venetoclax ramp-up cycle):

    • Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on days 3 through 28
    • Inqovi (35 mg decitabine / 100 mg cedazuridine): one tablet orally once daily on days 1 to 5
    • Antifungal prophylaxis should accompany the venetoclax ramp-up per institutional protocol and the venetoclax prescribing information

    Cycles 2 and beyond (28-day cycles):

    • Inqovi: one tablet orally once daily on days 1 to 5
    • Venetoclax: 400 mg orally once daily on days 1 to 28 (or per dose modification per prescribing information)

    Inqovi tablets should be taken at approximately the same time each day. They can be taken with or without food. The tablet should be swallowed whole; do not cut, crush, or chew. If a dose is missed, it should be taken as soon as possible on the same day. If the day has passed, the missed dose should be skipped and the next dose taken at the regular scheduled time.

    Where This Approval Fits: Inqovi’s Full Indication Picture

    With this approval, Inqovi now carries three FDA-approved indications across blood cancers:

    IndicationDatePartner drug
    Myelodysplastic syndromes (MDS), including CMMLJuly 2020None (monotherapy)
    Newly diagnosed AML, intensive chemotherapy-ineligibleMay 13, 2026Venetoclax (Venclexta)

    The progression from MDS/CMML monotherapy to AML combination therapy reflects the well-established clinical overlap between these diseases. Many patients with high-risk MDS progress to AML, and the HMA mechanism is active across the disease spectrum. The ability to use the same oral drug platform in both MDS and AML simplifies the treatment transition for patients who progress from one to the other.

    For Patients and Caregivers

    Who qualifies?

    Adults newly diagnosed with AML who are either 75 years or older, or who have comorbidities (organ dysfunction, severe frailty, concurrent illness) that make intensive induction chemotherapy unsafe. This is not a designation based solely on age: younger patients with significant comorbidities may also qualify.

    What does all-oral treatment mean practically?

    The five-day Inqovi dosing window (days 1 to 5 of each cycle) combined with daily venetoclax means treatment is taken at home throughout each 28-day cycle. There is no scheduled infusion clinic requirement for the regimen itself. Blood count monitoring, toxicity assessment, and clinical follow-up still require clinic visits, but not for drug administration.

    This is a genuinely meaningful practical change for patients who live alone, lack reliable transportation, or have mobility limitations. The drug is given at home, and patients control their own administration schedule within the 5-day window.

    Questions to discuss with your hematologist

    • Do my specific AML genetics (cytogenetics, molecular markers) suggest I am likely to respond to an HMA/BCL-2 approach?
    • Should I be tested for TP53, FLT3, IDH1/2, or other mutations that might inform therapy selection?
    • How will venetoclax drug interactions with my current medications be managed, particularly if I am on antifungal prophylaxis?
    • What blood count monitoring schedule is appropriate for my regimen?
    • What are the early signs of differentiation syndrome and when should I call the oncology team?

    For patients and families navigating a new AML diagnosis, the Leukemia and Lymphoma Society provides patient-facing disease information, clinical trial databases, and financial assistance resources. AAMDSIF (Aplastic Anemia and MDS International Foundation) covers the full MDS and AML spectrum with educational materials specific to these diseases. The NCI AML information page provides current treatment guidance in patient-accessible language.

    For related coverage on venetoclax and its expanding role in blood cancers, including the first all-oral AML regimen and the Immgolis biosimilar approvals relevant to RA and UC, see our venetoclax coverage on Health Evidence Digest.

    Sources

    FDA approval announcement: FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia. FDA.gov. May 13, 2026.

    Taiho Oncology press release: U.S. FDA Approves INQOVI in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy. businesswire.com. May 13, 2026.

    Cancer Therapy Advisor approval coverage: All-Oral Inqovi Regimen Approved for Newly Diagnosed AML. cancertherapyadvisor.com. May 2026.

    AJMC approval coverage: FDA Approves First All-Oral Regimen for AML. ajmc.com. May 2026.

    Targeted Oncology approval coverage: FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Unfit AML. targetedonc.com. May 2026.

    OncLive approval coverage: FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML. onclive.com. May 2026.

    CancerNetwork ASCO 2025 results: Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML. cancernetwork.com. 2025.

    AJMC ASCO 2025 summary: All-Oral AML Therapy: Decitabine-Cedazuridine Plus Venetoclax. ajmc.com. July 2025.

    ASCERTAIN-V trial registration: NCT04657081. ClinicalTrials.gov.

    Inqovi original MDS/CMML FDA approval: FDA approves decitabine and cedazuridine for treatment of adults with myelodysplastic syndromes. FDA.gov. July 2020.

    Venetoclax AML FDA approval: FDA approves venetoclax in combination for treatment of adults with newly diagnosed acute myeloid leukemia. FDA.gov.

    Decitabine mechanism: Decitabine. StatPearls. NCBI.

    DNA methylation and HMA therapy: DNA Hypomethylating Agents in Myeloid Malignancies. PMC4207474.

    Cedazuridine mechanism: Cedazuridine pharmacology. PMC7965890.

    BCL-2 and venetoclax: BCL-2 Inhibitors in Hematologic Malignancies. PMC8626879.

    AML overview: Acute Myeloid Leukemia. American Cancer Society.

    ASCO 2025 Annual Meeting: ASCO 2025 Annual Meeting. asco.org.

    EHA Congress 2025: EHA Congress 2025. ehaweb.org.

    Patient resources: Leukemia and Lymphoma Society | AAMDSIF | NCI AML Treatment (PDQ) | ClinicalTrials.gov: AML

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for acute myeloid leukemia, including eligibility for intensive versus less intensive regimens, should be made in close consultation with a board-certified hematologist or hematologic oncologist familiar with the patient’s full disease characteristics, performance status, and comorbidity profile.
  • Fasenra Just Got a Third Approved Indication. Here Is What Hypereosinophilic Syndrome Is and What the NATRON Trial Data Actually Shows.

    Fasenra Just Got a Third Approved Indication. Here Is What Hypereosinophilic Syndrome Is and What the NATRON Trial Data Actually Shows.

    📌 The essentials On May 13, 2026, the FDA approved Fasenra (benralizumab, AstraZeneca) for the treatment of adults and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. This is Fasenra’s third FDA-approved indication, joining severe eosinophilic asthma (approved 2017) and eosinophilic granulomatosis with polyangiitis (EGPA, approved 2022). On May 21, 2026, the European Medicines Agency’s CHMP issued a positive opinion recommending EU approval of Fasenra for HES (as part of a label update also covering severe asthma and EGPA). The clinical basis: Phase 3 NATRON trial (NCT04191304), published in Nature Medicine on March 31, 2026, enrolling 133 patients with HES (67 benralizumab, 66 placebo), 24 weeks, randomized double-blind placebo-controlled. Primary endpoint: 65% reduction in risk of first HES flare (HR 0.35; 95% CI 0.18 to 0.69; p=0.0024). All secondary endpoints met, including 66% reduction in annualized flare rate (0.41 versus 1.23 flares/year), 92% reduction in risk of hematologic relapse (HR 0.08; p less than 0.0001), and significant improvement in patient-reported fatigue by week 4. Dosing: 30 mg subcutaneous injection once every 4 weeks (different from the loading dose schedule used in asthma). Fasenra is the second anti-eosinophil biologic approved for HES, after mepolizumab (Nucala, approved 2020).

    Hypereosinophilic syndrome (HES) is a condition most people have never heard of. Most primary care providers encounter it rarely if at all. And for the approximately 30,000 to 200,000 Americans estimated to be living with it, that relative unfamiliarity often means years of unexplained symptoms, difficult diagnoses, and limited treatment options.

    On May 13, 2026, the FDA approved Fasenra (benralizumab) for HES, making it the second targeted biologic approved for this rare condition and the first approved for patients as young as 12. The pivotal trial behind the approval, NATRON, was published in Nature Medicine and met all of its endpoints, including a clinically meaningful reduction in flares, a striking near-elimination of hematologic relapse risk, and the first statistically significant improvement in fatigue ever demonstrated in a Phase 3 HES trial.

    This post covers what HES is and why it is hard to diagnose and treat, how benralizumab works, what every NATRON endpoint showed, and what this approval means for patients and clinicians navigating this condition.

    What Hypereosinophilic Syndrome Is

    Eosinophils are a type of white blood cell that normally account for less than 5% of circulating leukocytes. They are part of the immune system’s response to parasitic infections and play a role in allergic inflammation. In healthy adults, the normal eosinophil count is below 500 cells per microliter of blood.

    HES is defined by three criteria: a blood eosinophil count of 1,500 cells per microliter or higher, persisting for more than one month; evidence of eosinophil-mediated organ or tissue damage; and exclusion of identifiable secondary causes for the eosinophilia.

    When eosinophils are persistently elevated and activated, they infiltrate tissues throughout the body and release toxic granule proteins that damage the organs they contact. The damage is cumulative and organ-agnostic: any tissue can be affected. The most common sites of involvement include the lungs, skin, gastrointestinal tract, and heart. Eosinophilic heart disease, including Loeffler endocarditis, is one of the most serious and potentially fatal complications, with thrombus formation, valvular damage, and restrictive cardiomyopathy all documented.

    HES is not one disease: the subtypes matter clinically HES is a heterogeneous group of disorders, not a single entity. The classification includes: myeloproliferative HES, driven by a clonal eosinophil proliferation (the FIP1L1::PDGFRA fusion gene is the most common driver); lymphocytic variant HES, where an abnormal T-cell clone produces excess IL-5; idiopathic HES, where no underlying driver is identified; familial HES; and HES associated with other conditions. The NATRON trial specifically excluded patients with FIP1L1::PDGFRA-positive myeloproliferative HES, because those patients typically respond to imatinib (a tyrosine kinase inhibitor) and represent a distinct pathophysiology. The trial also required patients to be corticosteroid-responsive. The approved indication similarly excludes patients with an identifiable non-hematologic secondary cause. Clinicians should confirm these criteria before prescribing.

    HES is rare, with an estimated U.S. prevalence of 0.3 to 6.3 cases per 100,000 persons, but the true prevalence is likely underestimated due to diagnostic challenges. The condition can present with a wide and non-specific symptom spectrum: weight loss, fever, cough, chest pain, abdominal pain, skin rash, and neurological symptoms are all documented. Many patients spend years cycling through specialist consultations before a diagnosis is established. In the NATRON trial population, the mean time from first HES symptom appearance to enrollment was more than 8 years.

    The Disease Burden That NATRON Was Designed to Measure

    The NATRON trial population reflects what HES looks like in clinical practice. Of the 133 enrolled patients (median age 51, range 14 to 87 years, 61.7% female):

    • Most commonly involved organs were the lungs (35.6%), skin (25.3%), and gastrointestinal tract (21.8%)
    • 39.1% had experienced 2 HES flares in the prior 12 months; 36.8% had experienced 3 or more
    • Mean time since first HES symptoms was more than 8 years; mean time since diagnosis was nearly 5 years
    • Mean baseline PROMIS Fatigue T-score was 55.1, a score indicating clinically significant fatigue burden (population mean is 50; higher scores indicate worse fatigue)
    • Mean blood eosinophil count at baseline was 1,960 cells per microliter

    The flare definition used in NATRON is clinically meaningful: a flare required evidence of new or worsening HES clinical manifestations or laboratory abnormalities that resulted in hospitalization, or an increase in oral corticosteroid dose of at least 10 mg per day for at least 2 days, or the addition of new cytotoxic or immunosuppressive therapy. These are genuine clinical events with real consequences, not surrogate biomarker changes.

    How Benralizumab Works in HES

    Benralizumab is a humanized, afucosylated monoclonal antibody targeting the alpha subunit of the interleukin-5 receptor (IL-5Rα). IL-5 is the primary cytokine driving eosinophil production, maturation, survival, and activation. By binding IL-5Rα directly on eosinophils and their precursors (rather than binding the IL-5 ligand itself, as mepolizumab does), benralizumab triggers antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer cells, producing rapid and near-complete depletion of blood and tissue eosinophils within days of the first injection.

    The afucosylation engineering is the key pharmacological innovation that distinguishes benralizumab from mepolizumab within the anti-IL-5 class. By removing a fucose sugar from the antibody’s Fc region, the modified antibody binds Fc-gamma receptor IIIa on NK cells with much higher affinity, dramatically enhancing the ADCC-driven cell killing. This mechanism produces a more rapid and more complete eosinophil depletion than IL-5 ligand blocking alone.

    In HES, the downstream consequence of this eosinophil depletion is reduced tissue infiltration, less release of eosinophil granule proteins that damage organs, and a lower risk of the inflammatory flares that drive clinical worsening and organ damage. The NATRON data confirms that this biological effect translates to clinically meaningful outcomes.

    The NATRON Trial: All the Numbers

    Design

    NATRON (NCT04191304) was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Eligible patients were aged 12 years and older, FIP1L1::PDGFRA-negative, with HES flare signs or symptoms at screening or at least 2 flares in the prior year, and confirmed corticosteroid-responsive disease. Patients were randomized 1:1 to benralizumab 30 mg or placebo subcutaneously every 4 weeks, on top of stable background HES therapy, for a 24-week double-blind treatment period.

    Primary endpoint

    OutcomeBenralizumab (n=67)Placebo (n=66)
    Patients with first HES flare19.4%42.4%
    Risk of first flare (HR)0.35 (95% CI 0.18 to 0.69)Reference
    p-value0.0024—
    Flare risk reduction65%—

    The primary endpoint was met with a hazard ratio of 0.35, meaning patients on benralizumab had only 35% of the flare risk of placebo-treated patients. The Kaplan-Meier curves separated early and continued to diverge, with benralizumab-treated patients maintaining lower flare risk throughout the 24-week observation period.

    Key secondary endpoints (all statistically significant)

    OutcomeBenralizumabPlaceboEffect size and significance
    Proportion with HES flares22.4%45.5%OR 0.31 (95% CI 0.14 to 0.69); p=0.0033
    Annualized flare rate0.41 flares/year1.23 flares/yearRR 0.34 (95% CI 0.18 to 0.63); p=0.0008
    Risk of hematologic relapseHR 0.08 (95% CI 0.03 to 0.20)Referencep less than 0.0001; 92% risk reduction
    PROMIS Fatigue improvement at Week 24LS mean difference vs placebo: −4.72Reference95% CI −7.64 to −1.80; p=0.0017
    Fatigue improvement onsetBy Week 4—Sustained to Week 24

    Source: Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8. NATRON NCT04191304.

    The hematologic relapse endpoint, defined as blood eosinophil count rising above 1,000 cells per microliter after confirmed depletion, showed a 92% risk reduction with benralizumab. This near-elimination of hematologic relapse reflects the drug’s mechanism: near-complete eosinophil depletion from the first dose, sustained throughout the dosing period.

    The fatigue endpoint is clinically important and worth highlighting. HES-related fatigue is one of the most commonly reported and most disabling symptoms in the condition. The NATRON PROMIS Fatigue results are the first statistically significant improvement in patient-reported fatigue from a Phase 3 HES trial. The fact that the improvement was detectable by week 4, after just the first monthly injection, and sustained to week 24, is a meaningful signal that the biological effect is rapid and durable.

    What PROMIS Fatigue measures and why a difference of 4.72 points is clinically meaningful The PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue Short Form 7a is a validated, standardized questionnaire assessing fatigue severity and impact over the previous 7 days. Scores are T-scored to a general population mean of 50, with higher scores indicating worse fatigue. The NATRON population had a mean baseline score of 55.1, indicating a clinically significant fatigue burden above population norms. A difference of 4.72 points is consistent with published minimally important difference thresholds for PROMIS Fatigue in chronic disease populations, generally estimated at 4 to 6 points. The improvement therefore exceeds the threshold for clinical meaningfulness, not just statistical significance.

    Safety

    The safety profile of benralizumab in NATRON was consistent with its well-established profile from seven years of use in severe asthma. Crucially, the overall adverse event rate was similar between groups: 64.2% in the benralizumab arm versus 66.7% with placebo, and serious adverse events occurred at virtually identical rates (7.5% versus 7.6%). This parity in overall adverse event burden, combined with a substantially better efficacy profile, is what the FDA reviewed in establishing a favorable benefit-risk balance.

    The most common adverse reactions in the HES population (occurring in 5% or more of benralizumab-treated patients and more frequently than placebo) were headache, hypersensitivity reactions (including urticaria, papular urticaria, and rash), and influenza-like illness. The adolescent patients (aged 12 to 17) in the trial had safety and tolerability results consistent with adults.

    Where Benralizumab Fits in HES Treatment

    Before discussing how benralizumab fits into HES management, it is worth acknowledging that the treatment landscape for HES remains relatively underdeveloped compared to more common eosinophilic conditions.

    The standard treatment for HES has historically been high-dose oral corticosteroids, which effectively suppress eosinophils and reduce symptoms but carry well-known long-term toxicity including osteoporosis, weight gain, diabetes, infections, and adrenal suppression. Patients on chronic steroids for HES accumulate organ damage from both the disease and the treatment.

    Imatinib (Gleevec) is the first-line agent for FIP1L1::PDGFRA-positive myeloproliferative HES, which is excluded from both the Fasenra and Nucala approvals.

    Mepolizumab (Nucala, GSK) was approved for HES in adults in 2020, as the first targeted anti-IL-5 agent for this indication, based on the Phase 3 EXPLORER trial showing a 50% reduction in the risk of HES worsening.

    Benralizumab now adds a second biologic option, with a 65% flare risk reduction and the additional advantages of near-complete eosinophil depletion (versus partial reduction with mepolizumab), once-monthly dosing throughout treatment (versus monthly loading then quarterly dosing with mepolizumab after the first three doses), and a pediatric indication down to age 12 (mepolizumab is approved for adults only in HES).

    Benralizumab vs. mepolizumab in HES: what the data comparison suggests No head-to-head trial comparing benralizumab and mepolizumab in HES has been conducted, and cross-trial comparisons are methodologically unreliable. The EXPLORER trial (mepolizumab) enrolled 108 patients and showed 50% reduction in HES worsening; NATRON enrolled 133 patients and showed 65% reduction in flare risk. The patient populations, flare definitions, and time periods differed in ways that make numerical comparison inappropriate. What is appropriate to note is that both drugs reduce eosinophils via the IL-5 pathway and both have demonstrated meaningful clinical benefit in HES. The mechanistic distinction (receptor blockade with direct eosinophil depletion versus ligand blockade with partial reduction) may matter more in individual patients with high eosinophil burden or disease that is incompletely controlled on mepolizumab. The choice between them will ultimately depend on prescriber experience, patient-specific factors, and in some cases prior response to one agent.

    Dosing: An Important Difference From the Asthma and EGPA Schedule

    Clinicians already prescribing Fasenra for severe asthma or EGPA should note that the dosing schedule for HES is different.

    For severe asthma: 30 mg every 4 weeks for the first 3 doses, then 30 mg every 8 weeks thereafter.

    For EGPA and HES: 30 mg once every 4 weeks throughout treatment. No switch to an every-8-week schedule.

    This distinction matters for prescription writing, patient counseling, and specialty pharmacy dispensing. Patients should receive a clear explanation that their dosing schedule differs from what they may have read about Fasenra in the asthma context.

    Administration: subcutaneous injection into the upper arm, thigh, or abdomen. Can be administered by a healthcare provider or by self-injection after proper training.

    What Patients and Caregivers Should Know

    Who is this approval for?

    Adults and pediatric patients aged 12 years and older with HES that does not have an identifiable non-hematologic secondary cause, and specifically FIP1L1::PDGFRA-negative disease. If you have been diagnosed with HES and are currently managing the condition with oral corticosteroids or other systemic therapies with inadequate control or significant side effects, Fasenra is now an FDA-authorized option to discuss with your hematologist or allergist-immunologist.

    When to involve a specialist

    HES is a rare condition that requires specialist expertise for accurate diagnosis and management. Hematologists, allergist-immunologists, and in some cases rheumatologists or pulmonologists depending on organ involvement are the specialists most experienced with HES diagnosis and treatment. Because the condition is rare, specialized centers with multi-disciplinary eosinophilia programs (several are affiliated with academic medical centers in the United States) often have the most experience with the full diagnostic workup, including genetic testing for FIP1L1::PDGFRA and lymphocytic variant HES markers.

    Patient support

    The American Partnership for Eosinophilic Disorders (APFED) is the primary patient advocacy organization for eosinophilic conditions in the United States and maintains updated resources on HES including a specialist referral network. The Hypereosinophilic Syndrome Research Program at NIH through the National Institute of Allergy and Infectious Diseases has been a leading center for HES research and may have open clinical trials. The National Organization for Rare Disorders (NORD) maintains a current clinical overview of HES.

    For related HED coverage on other biologic approvals in eosinophilic conditions, see our post on Trimbow, the first single-inhaler triple therapy for uncontrolled asthma, and our post on Fasenra’s companion indication in EGPA and the broader role of anti-IL-5 biologics in eosinophilic inflammation.

    Sources

    FDA approval announcement: FDA approves benralizumab (Fasenra) for hypereosinophilic syndrome. FDA.gov. May 13, 2026.

    AstraZeneca US press release: FASENRA approved in US for hypereosinophilic syndrome. astrazeneca-us.com. May 14, 2026.

    NATRON primary publication (Nature Medicine): Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8.

    NATRON ACAAI 2025 abstract (Annals of Allergy): Benralizumab for patients with hypereosinophilic syndrome: A randomized, double-blind, placebo-controlled phase 3 trial (NATRON). Ann Allergy Asthma Immunol. November 2025.

    NATRON full results (AstraZeneca press release, November 2025): Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show Fasenra delayed time to first flare. astrazeneca.com.

    NATRON trial registration: NCT04191304. ClinicalTrials.gov.

    EMA CHMP positive opinion (May 21, 2026): Fasenra. EMA. ema.europa.eu.

    PharmExec FDA approval coverage: FDA Approves Fasenra for Hypereosinophilic Syndrome. pharmexec.com. May 2026.

    Pulmonology Advisor NATRON coverage: Add-On Benralizumab Effective in Hypereosinophilic Syndrome. pulmonologyadvisor.com.

    NATRON design paper (Blood/ASH 2023): The Phase 3 NATRON Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics. Blood. 2023.

    HES GARD overview: Hypereosinophilic Syndrome. rarediseases.info.nih.gov.

    HES StatPearls: Hypereosinophilic Syndrome. StatPearls. NCBI.

    Eosinophil biology: Eosinophils. StatPearls. NCBI.

    Benralizumab mechanism (afucosylation and ADCC): Anti-IL-5 and IL-5Rα biologics: mechanisms and clinical evidence. PMC7186825.

    Eosinophilic heart disease: Cardiac Manifestations in Hypereosinophilic Syndrome. PMC5454610.

    Mepolizumab HES FDA approval: FDA approves mepolizumab for treatment of hypereosinophilic syndrome. FDA.gov.

    PROMIS Fatigue instrument: PROMIS Adult Measures: Fatigue. healthmeasures.net.

    Corticosteroids overview: Corticosteroids. StatPearls. NCBI.

    Fasenra prescribing information: FASENRA (benralizumab) Prescribing Information. AstraZeneca. 2026.

    Patient resources: American Partnership for Eosinophilic Disorders (APFED) | NIH HES Research Program (NIAID) | NORD: Hypereosinophilic Syndrome | ClinicalTrials.gov: HES

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Hypereosinophilic syndrome requires accurate diagnosis and specialist management. Treatment decisions should be made in consultation with a qualified allergist-immunologist or hematologist experienced in eosinophilic conditions.
  • A Blood Test After Bladder Cancer Surgery Can Now Guide Whether You Need Immunotherapy. The FDA Just Approved the First-Ever ctDNA-Guided Cancer Treatment.

    A Blood Test After Bladder Cancer Surgery Can Now Guide Whether You Need Immunotherapy. The FDA Just Approved the First-Ever ctDNA-Guided Cancer Treatment.

    📌  The essentials Drug approved: Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs), Genentech/Roche. FDA approval date: May 15, 2026. This is Tecentriq’s eleventh FDA-approved indication. Indication: Adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD), as determined by an FDA-authorized test. What makes it first-in-class: First ctDNA-guided therapy approval in oncology anywhere in the world. Treatment is triggered by what a serial blood test finds in the weeks after surgery, not by tumor staging alone. Companion diagnostic approved simultaneously: Signatera™ CDx (Natera, Inc.), the personalized ctDNA assay that identifies which patients have molecular residual disease and qualify for adjuvant treatment. Key trial results (IMvigor011, n=250 ctDNA-positive patients): DFS hazard ratio 0.64 (36% reduction in risk of recurrence or death, p less than 0.0001). OS hazard ratio 0.59 (41% reduction in risk of death). ctDNA-negative patients: Those who remained MRD-negative during serial monitoring had 2-year DFS of 88.4% and 2-year OS of 97.1% without receiving any adjuvant treatment. Dosing: Atezolizumab 840 mg IV every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks for up to 1 year, or until recurrence or unacceptable toxicity. Subcutaneous option (Tecentriq Hybreza, 1875 mg every 3 weeks) also approved.

    Nearly half of all patients with muscle-invasive bladder cancer who undergo surgical removal of the bladder will see their cancer return. This is one of the most difficult realities in urological oncology: the patient did everything right, underwent a major operation with significant impact on quality of life, and cancer came back anyway. Often within two years. Often aggressively.

    Oncologists have tried for decades to prevent this with adjuvant therapy: chemotherapy or immunotherapy given after surgery to eliminate any cancer cells that surgery may have missed. But a fundamental problem made this approach uncertain. Without a way to know which patients still had cancer cells circulating after surgery, clinicians had to treat everyone at high pathological risk and accept that a large proportion were receiving toxic treatment they did not need, while others with lower-risk staging but hidden disease received nothing.

    On May 15, 2026, the FDA approved a fundamentally different approach. Using a serial blood test to detect circulating tumor DNA in the weeks after cystectomy, clinicians can now identify exactly which patients still carry molecular evidence of residual cancer. Those who test positive receive adjuvant immunotherapy. Those who remain negative skip it, with data showing they have excellent outcomes without it.

    The FDA approval of Tecentriq (atezolizumab) for ctDNA MRD-guided adjuvant treatment of muscle-invasive bladder cancer is the first approval of a ctDNA-guided therapy in oncology history. The companion diagnostic, Natera’s Signatera CDx, was approved the same day. Together they represent what the field has called a new paradigm: treating cancer not based on where it was, but on whether residual evidence of it remains.

    Muscle-Invasive Bladder Cancer: Why Adjuvant Therapy Has Been Such a Hard Problem

    Bladder cancer is the sixth most common cancer in the United States, with approximately 82,000 new diagnoses annually. The majority are non-muscle-invasive at diagnosis and have a relatively good prognosis with local treatment. Muscle-invasive bladder cancer (MIBC), which has penetrated the muscular wall of the bladder, is diagnosed in roughly 25% of cases and carries a substantially worse prognosis.

    Standard treatment for MIBC is radical cystectomy, the surgical removal of the bladder, with or without prior neoadjuvant cisplatin-based chemotherapy. Even with optimal surgical care, nearly half of patients experience disease recurrence within two years, predominantly as distant metastases. At the time progression is detected radiographically, some patients are already too ill to receive further systemic therapy. Earlier intervention, before relapse becomes clinically visible, is the clinical goal.

    Why the prior approach to adjuvant therapy failed in unselected patients The IMvigor010 trial, which directly preceded IMvigor011, tells the story of why patient selection matters. IMvigor010 evaluated adjuvant atezolizumab versus observation in unselected patients with high-risk MIBC after cystectomy. It found no statistically significant improvement in disease-free survival or overall survival with atezolizumab in the overall population. The question that emerged from the failed IMvigor010 result was not whether atezolizumab could work in bladder cancer, but whether the right patients were being selected. A retrospective analysis of the IMvigor010 data identified that approximately 40% of the enrolled patients were ctDNA-positive after surgery. In that ctDNA-positive subgroup, atezolizumab showed a meaningful survival benefit. In ctDNA-negative patients, there was no benefit, because there was no residual cancer for the immune system to target. IMvigor011 was designed prospectively around this insight. Rather than treating all high-risk patients and hoping some would benefit, the study used serial ctDNA testing to identify and enrich the treatment population for the patients most likely to have residual microscopic disease. The result was a positive Phase 3 trial where IMvigor010 had failed, using a different patient selection strategy with the same drug.

    What Circulating Tumor DNA and Molecular Residual Disease Actually Mean

    Circulating tumor DNA (ctDNA) is small fragments of DNA shed by cancer cells into the bloodstream. In a patient without cancer, or whose cancer has been completely removed, ctDNA is absent or present at extremely low levels. In a patient with residual cancer cells after surgery, those cells continue to shed tumor-specific DNA into circulation, even before any tumor becomes visible on imaging.

    Molecular residual disease (MRD) refers to the presence of detectable cancer at a molecular level, below the threshold of conventional imaging. A patient may have a clear CT scan, clear pathology margins, and no palpable disease, but still have cancer cells circulating or seeded in distant sites at levels that no current imaging can detect. ctDNA testing is the most sensitive available method for detecting this residual disease.

    How Signatera™ works

    Natera’s Signatera CDx is a personalized, tumor-informed ctDNA assay. This means it is not a generic cancer blood test. Instead, it starts with whole-exome sequencing of the patient’s own tumor tissue to identify up to 16 mutations specific to that individual’s cancer. It then designs a custom PCR panel targeting exactly those mutations to look for them in blood samples over time. This personalization makes Signatera substantially more sensitive than tumor-agnostic ctDNA approaches for detecting low levels of residual disease.

    In IMvigor011, serial Signatera testing was performed at multiple time points during the year after cystectomy. Patients who converted from negative to positive during monitoring, or who were positive from the first post-surgical test, were classified as ctDNA MRD-positive and became eligible for the treatment phase. This serial approach identified a 30-day window around each positive test that expanded the period during which patients could be enrolled, rather than requiring a single test result to determine eligibility.

    The IMvigor011 Trial: Design and Results

    Trial design

    IMvigor011 (NCT04660344) is a global Phase 3, randomized, double-blind, placebo-controlled trial. A total of 761 patients with MIBC, no radiographic evidence of disease, and no prior systemic therapy for MIBC were enrolled in the surveillance phase within 6 to 24 weeks of radical cystectomy with lymph node dissection. These patients underwent serial ctDNA monitoring with Signatera for up to one year after surgery.

    Of the 761 enrolled, 250 tested ctDNA-positive and entered the treatment phase. They were randomized 2:1 to receive atezolizumab (n=167) or placebo (n=83) every 4 weeks for 12 cycles (approximately one year) or until disease recurrence or unacceptable toxicity. The primary endpoint was investigator-assessed disease-free survival (DFS). Overall survival (OS) was a key secondary endpoint.

    Efficacy results

    EndpointAtezolizumab (n=167)Placebo (n=83)
    Primary: DFS hazard ratio0.64 (95% CI 0.44 to 0.93)Reference
    Risk reduction in recurrence/death36%N/A
    DFS p-valuep less than 0.0001N/A
    OS hazard ratio0.59 (95% CI 0.37 to 0.94)Reference
    Risk reduction in death41%N/A
    PublicationNew England Journal of Medicine (NEJM)N/A
    Conference presentationESMO 2025 Presidential Symposium (LBA8)N/A

    Source: Powles T et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. NEJM. 2025. doi:10.1056/NEJMoa2511885. Presented at ESMO 2025, LBA8.

    A 41% reduction in the risk of death is a substantial survival benefit for an adjuvant setting, where the comparator is placebo (observation) and patients have no detectable disease on imaging. The publication in NEJM and the Presidential Symposium presentation at ESMO 2025 reflect the field’s recognition that this result represents a meaningful advance in bladder cancer care.

    The ctDNA-negative population: equally important findings

    Outcome in serial ctDNA-negative patients (n=171, no adjuvant treatment)Result
    DFS at 1 year95.4%
    DFS at 2 years88.4%
    OS at 1 year100%
    OS at 2 years97.1%
    Adjuvant treatment receivedNone

    Source: Natera IMvigor011 topline results. Presented at EAU 2024 and ESMO 2025.

    The ctDNA-negative data is as important to the clinical story as the treatment data. Patients who remain serially ctDNA-negative after cystectomy have a 97.1% two-year overall survival without receiving any adjuvant treatment. This means the ctDNA test is not just identifying who needs treatment; it is simultaneously identifying who can safely avoid it. In a disease where adjuvant immunotherapy carries meaningful toxicity and burden, sparing 60 to 70% of post-cystectomy patients from unnecessary treatment is a real clinical benefit.

    Why This Approval Matters Beyond Bladder Cancer

    The regulatory significance of this approval extends well beyond atezolizumab and bladder cancer. IMvigor011 is the first prospective Phase 3 trial anywhere in oncology to demonstrate that a ctDNA-guided treatment strategy produces statistically significant improvements in both DFS and OS. Every previous ctDNA study in the adjuvant setting had been retrospective or had not yet reported survival outcomes from a randomized controlled trial.

    The simultaneous approval of Signatera CDx as a companion diagnostic is the regulatory infrastructure that makes this a replicable model. By pairing a specific ctDNA assay with a specific drug in a specific indication, the FDA has established how ctDNA-guided therapy approvals work. Other drugs and other tumor types in which ctDNA monitoring is being studied now have a regulatory precedent to follow.

    ctDNA MRD-guided adjuvant strategies are already being investigated in colon cancer (DYNAMIC trial), lung cancer, breast cancer, and other solid tumors. IMvigor011’s success in bladder cancer, and its accompanying FDA approval, validates the paradigm and accelerates development in those other disease settings.

    What this means for how we think about ‘cancer-free’ after surgery For decades, ‘no evidence of disease’ after cancer surgery meant no visible tumor on imaging and clear margins on pathology. A patient who met those criteria was considered cancer-free and entered a watch-and-wait surveillance period. IMvigor011 establishes that ‘no evidence of disease’ on conventional imaging can coexist with detectable ctDNA in the bloodstream, and the presence of that ctDNA predicts a high probability of recurrence. The approval creates a new, more sensitive definition of post-surgical disease status and a new decision point: not just ‘is imaging clear?’ but ‘is the blood test clear?’ For patients, this changes the conversation after surgery. Serial ctDNA testing is now an FDA-authorized tool to determine whether adjuvant treatment is warranted. A positive result triggers a conversation about immunotherapy. A persistently negative result provides reassurance that the risk of early recurrence is low, and avoids unnecessary treatment.

    Safety: Immune-Mediated Adverse Reactions Are the Primary Consideration

    The safety profile of atezolizumab in IMvigor011 was consistent with its established profile across other approved indications. As a PD-L1 immune checkpoint inhibitor, the primary safety concern is immune-mediated adverse reactions: the immune system, once reinvigorated against cancer cells, can also attack healthy tissue.

    Immune-mediated adverse reactions can affect virtually any organ system and can range from mild and manageable to severe, life-threatening, or fatal. The systems most commonly involved include the lungs (pneumonitis), liver (hepatitis), intestines (colitis), endocrine glands (thyroid, pituitary, adrenal), kidneys, skin, and nervous system. Most are manageable with corticosteroids and, when necessary, discontinuation of atezolizumab.

    Patients receiving atezolizumab after cystectomy should be aware of the immune-mediated adverse reaction spectrum and know to report new or worsening symptoms promptly. Early detection of immune-mediated reactions improves outcomes. The prescribing information provides specific management guidance for each organ system.

    What Patients Who Have Had Bladder Cancer Surgery Should Know

    • Who is this approval for? Adults with muscle-invasive bladder cancer who have undergone radical cystectomy and who test positive for ctDNA MRD using serial Signatera CDx testing in the year after surgery. It is not for non-muscle-invasive bladder cancer or for patients who have already developed metastatic recurrence.
    • When does ctDNA testing happen? Serial testing begins within 6 to 24 weeks of cystectomy and continues for up to one year. Multiple tests are needed because the conversion from negative to positive can happen at any point during the surveillance window. A single negative test at one time point does not provide the same reassurance as persistently negative results across serial tests.
    • What happens if I test positive? A positive ctDNA MRD result identifies you as a candidate for adjuvant atezolizumab. Treatment lasts up to one year (approximately 12 cycles). Your oncologist will discuss the benefit-risk balance for your specific situation, including your kidney function, immune history, and other factors that may affect tolerability.
    • What happens if I test negative? Persistently ctDNA-negative results during the surveillance period indicate a low risk of early recurrence. The IMvigor011 data shows a 97.1% 2-year overall survival in this group without adjuvant treatment. Regular follow-up imaging continues, but adjuvant immunotherapy is not indicated.
    • Is Signatera CDx available now? The Signatera assay has been available commercially for ctDNA testing in several cancer types. The CDx designation for this specific MIBC + atezolizumab indication was granted May 15, 2026. Ask your urologist or oncologist about ordering serial Signatera testing as part of your post-cystectomy surveillance plan.

    Resources for bladder cancer patients and caregivers

    For patients navigating muscle-invasive bladder cancer treatment and post-surgical surveillance, the Bladder Cancer Advocacy Network (bcan.org) is the leading U.S. patient organization and maintains updated information on approved therapies, clinical trials, and specialist referral resources. For clinicians seeking the full IMvigor011 data, the primary results are published in the New England Journal of Medicine and were presented as a Presidential Symposium abstract at ESMO 2025. Information on Signatera CDx is available through Natera (natera.com).

    Sources

    FDA approval announcement: FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease. FDA.gov. May 15, 2026.

    Genentech press release: FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment. gene.com. May 15, 2026.

    Natera press release (full results): Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients. natera.com. October 2025.

    Primary publication (NEJM): Powles T et al. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025. doi:10.1056/NEJMoa2511885.

    Renal and Urology News: FDA Approves Atezolizumab for ctDNA-Guided Adjuvant MIBC Treatment. renalandurologynews.com. May 2026.

    OncoDaily trial summary: IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer. oncodaily.com.

    Urology Times (ESMO results): ctDNA-guided atezolizumab boosts survival in muscle-invasive bladder cancer. urologytimes.com. February 2026.

    Oncology News Central (ESMO presentation): IMvigor011 Data at ESMO 2025 Show ctDNA-Guided Adjuvant Atezolizumab Improves Survival in Bladder Cancer. oncologynewscentral.com.

    Targeted Oncology (landmark designation): Landmark IMvigor011 Trial Validates ctDNA-Guided MIBC Therapy. targetedonc.com. March 2026.

    IMvigor010 background context: Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial. Eur Urol. 2024;85(2):114-122.

    Trial registration: IMvigor011 (NCT04660344). A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab in Patients With MIBC Who Have ctDNA Detectable Disease After Surgery. clinicaltrials.gov.

    Patient resources: Bladder Cancer Advocacy Network: bcan.org; Signatera CDx information: natera.com/oncology/signatera/

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for muscle-invasive bladder cancer, including ctDNA testing and adjuvant immunotherapy, should be made in close consultation with a qualified urologic oncologist experienced in bladder cancer management.
  • The First Biosimilars to Simponi and Simponi Aria Just Got FDA Approval. Here Is What Immgolis and Immgolis Intri Are, What They Treat, and Why You Cannot Buy Them Yet.

    The First Biosimilars to Simponi and Simponi Aria Just Got FDA Approval. Here Is What Immgolis and Immgolis Intri Are, What They Treat, and Why You Cannot Buy Them Yet.

    📌 The essentials On May 15, 2026, the FDA approved Immgolis (golimumab-sldi, Accord BioPharma) as an interchangeable biosimilar to Simponi (golimumab, Janssen), and Immgolis Intri (golimumab-sldi) as an interchangeable biosimilar to Simponi Aria (golimumab, Janssen). These are the first FDA-approved biosimilars to either reference product. Both share the same INN suffix: golimumab-sldi. Developed by Bio-Thera Solutions; commercialized in the U.S. by Accord BioPharma (a subsidiary of Intas Pharmaceuticals). Immgolis approved indications: adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, and adults with moderately to severely active ulcerative colitis (UC). Immgolis Intri approved indication: adults with moderately to severely active RA in combination with methotrexate only. Administration: Immgolis is subcutaneous injection (prefilled syringe); Immgolis Intri is intravenous infusion (single-dose vial). Both carry interchangeable designation, meaning pharmacists may substitute them at the counter without calling the prescriber, subject to state law. Critical caveat for patients: Accord BioPharma plans to make both products commercially available in Q4 2026. Launch is uncertain due to active BPCIA patent litigation filed by Janssen. Janssen filed a motion for preliminary injunction on May 6, 2026. A hearing is expected August to September 2026.

    Golimumab (Simponi, Simponi Aria) is a fully human monoclonal antibody that blocks tumor necrosis factor alpha (TNF-alpha), the inflammatory cytokine that drives joint destruction in rheumatoid arthritis and the mucosal inflammation in ulcerative colitis. It is one of five TNF inhibitors currently approved in the United States. It generated approximately $1.19 to $1.2 billion in U.S. sales in 2025, making it a significant commercial target for biosimilar entry. And until May 15, 2026, not a single FDA-approved biosimilar existed for either formulation.

    That changed when the FDA granted approval to Immgolis and Immgolis Intri, both developed by Bio-Thera Solutions and to be commercialized in the United States by Accord BioPharma. Both carry the coveted interchangeable designation, meaning pharmacists can substitute them for a Simponi or Simponi Aria prescription at the counter without contacting the prescriber first, in states where such substitution is permitted.

    Whether patients will actually be able to access these products in the near term is a different question entirely. Active patent litigation filed by Janssen, including a preliminary injunction motion already before a federal court, means the actual launch date is uncertain even though the regulatory hurdle has been cleared.

    This post covers what golimumab is and who uses it, what makes Immgolis and Immgolis Intri different from each other, what the interchangeable designation means in practice, why the Janssen lawsuit matters for access, and what patients on Simponi or Simponi Aria should know right now.

    What Golimumab Is and Why It Matters in Autoimmune Disease

    Golimumab is a fully human IgG1 monoclonal antibody that binds with high affinity and specificity to both soluble and transmembrane forms of human TNF-alpha, preventing it from interacting with its receptors on cell surfaces. TNF-alpha is a central mediator of the inflammatory cascade in multiple immune-mediated conditions. By neutralizing TNF-alpha, golimumab interrupts the downstream signaling that produces joint inflammation, synovial destruction, and intestinal mucosal damage.

    When golimumab binds TNF-alpha, multiple pro-inflammatory biomarkers fall measurably: C-reactive protein (CRP), interleukin-6 (IL-6), intercellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) all decline. These reductions reflect the broad anti-inflammatory effect of TNF blockade at multiple downstream steps.

    Golimumab is currently approved under two brand names with distinct delivery formats:

    Simponi (golimumab) is a subcutaneous injection given once monthly using a prefilled syringe or autoinjector. It is approved for:

    Simponi Aria (golimumab) is an intravenous infusion given at weeks 0 and 4, then every 8 weeks thereafter. It is approved for:

    • Moderately to severely active rheumatoid arthritis in combination with methotrexate

    The two formulations are not interchangeable with each other: the same molecule is used at different doses and via different administration routes for different indications. This distinction carries through to the biosimilars as well.

    Immgolis vs. Immgolis Intri: Two Products, One Molecule, Important Differences

    Both Immgolis and Immgolis Intri share the same INN (international nonproprietary name): golimumab-sldi. They are derived from the same manufacturing process. However they are distinct products with distinct approved indications and routes of administration, and they should not be used interchangeably with each other.

    Immgolis (golimumab-sldi)Immgolis Intri (golimumab-sldi)
    Reference productSimponi (golimumab)Simponi Aria (golimumab)
    Route of administrationSubcutaneous injection (prefilled syringe)Intravenous infusion (single-dose vial)
    Approved for RAYes, in combination with methotrexateYes, in combination with methotrexate
    Approved for UCYes (moderately to severely active)No
    Approved for ankylosing spondylitisNo (not part of current approval)No
    Approved for psoriatic arthritisNo (not part of current approval)No
    Interchangeable designationYesYes
    Commercially availableQ4 2026 (pending litigation outcome)Q4 2026 (pending litigation outcome)

    The indication scope of Immgolis and Immgolis Intri does not cover all of the indications currently on Simponi’s and Simponi Aria’s labels. Specifically, ankylosing spondylitis and psoriatic arthritis indications from the Simponi label are not included in the current Immgolis approval. Patients using Simponi for ankylosing spondylitis or psoriatic arthritis should not assume Immgolis is interchangeable for their specific indication until confirmed with their prescriber and insurer.

    What Interchangeable Designation Means Here

    Both Immgolis and Immgolis Intri received interchangeable designation from the FDA, the highest standard available for a biosimilar. This requires not only demonstrating biosimilarity (highly similar structure, function, and safety to the reference product) but also completing switching studies showing that patients who alternate between the biosimilar and the reference product do not experience greater risk or reduced efficacy compared to patients who remain on either product alone.

    In practical terms, interchangeable designation means:

    • A pharmacist can substitute Immgolis for a Simponi prescription without contacting the prescriber first, in states that permit pharmacy-level substitution
    • A pharmacist can substitute Immgolis Intri for a Simponi Aria prescription under the same conditions
    • The FDA has determined that switching between the biosimilar and the reference product is clinically appropriate

    The evidence basis for both approvals was described by the FDA as a comprehensive review of structural and functional product quality attributes, including those known to affect safety and efficacy, plus a human pharmacokinetic similarity study showing comparable drug exposure and immunogenicity results between Immgolis and Simponi.

    For a broader explanation of how biosimilar and interchangeable designations work and why the distinction matters at the pharmacy counter, see our post on PONLIMSI and the denosumab biosimilar landscape, which covers this regulatory framework in detail.

    Safety: The Boxed Warning and What Patients and Clinicians Need to Know

    Immgolis and Immgolis Intri carry the same boxed warnings as their reference products. These warnings apply to the golimumab molecule regardless of which manufacturer produces it.

    Boxed warning: serious infections and malignancy TNF inhibitors including golimumab increase the risk of serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections, and infections due to other opportunistic pathogens. Testing for latent tuberculosis is required before initiating therapy. Treatment of latent TB must be completed before starting golimumab in most cases. Monitor all patients for signs and symptoms of active infection during treatment. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. Immgolis and Immgolis Intri are not approved for use in pediatric patients. In adult patients, an increased rate of lymphoma relative to the general population has been observed. The overall benefit-risk profile remains favorable for the approved indications, but the malignancy risk is a labeled concern requiring monitoring.

    Additional warnings and precautions:

    • Hepatitis B reactivation: Screen for HBV infection before initiating treatment. Patients who are HBV surface antigen positive require antiviral prophylaxis in most cases. Fatal HBV reactivation has been reported with TNF inhibitors.
    • Demyelinating disorders: New onset or exacerbation of central and peripheral demyelinating disorders, including multiple sclerosis, have been reported with TNF blockers. Discontinue if these develop.
    • Heart failure: Worsening or new-onset congestive heart failure has been reported. Avoid use in patients with moderate to severe heart failure.
    • Autoimmune reactions: Drug-induced lupus-like syndrome is rare but reported. Discontinue if suspected.
    • Live vaccines: Do not administer live vaccines to patients receiving golimumab products. The diminished immune response may make vaccines less effective and live vaccines may cause infections.
    • Concomitant biologics: Use with abatacept, anakinra, or other biologic DMARD combinations increases the risk of serious infections and is generally not recommended.

    Common adverse events from golimumab clinical experience include upper respiratory tract infections, nasopharyngitis, and injection site reactions for the subcutaneous formulation, and infusion-related reactions for the IV formulation.

    The Janssen Patent Litigation: Why the Launch Date Is Uncertain

    This is the most important practical piece of information for patients considering these products.

    Regulatory approval and commercial availability are two distinct things, and the gap between them in this case is substantial.

    The timeline of the litigation:

    • March 3, 2026: Janssen Biotech Inc. and Janssen Sciences Ireland UC filed a BPCIA (Biologics Price Competition and Innovation Act) patent infringement complaint against Bio-Thera Solutions and Accord BioPharma in the U.S. District Court for the District of Delaware (Case No. 1:26-cv-00222). The complaint asserts infringement of 17 patents related to golimumab, spanning manufacturing claims, method-of-treatment claims, and composition claims.
    • March 20, 2026: Accord, Intas, and Bio-Thera filed four inter partes review (IPR) petitions at the USPTO challenging four of the Janssen patents. The challenged patents cover method-of-treatment claims related to intravenous golimumab dosing.
    • May 6, 2026: Janssen filed a motion for preliminary injunction, seeking a court order that would block Accord and Bio-Thera from launching Immgolis and Immgolis Intri in the United States while the patent case is decided.
    • June 8, 2026: Accord BioPharma and Bio-Thera’s responsive brief to the preliminary injunction motion is due.
    • August to September 2026: Preliminary injunction hearing expected.
    • Q4 2026: Accord BioPharma’s stated launch target, which is contingent on the litigation outcome.
    What a BPCIA preliminary injunction means The Biologics Price Competition and Innovation Act created specific procedures for patent disputes between reference product sponsors (like Janssen) and biosimilar applicants. A preliminary injunction is a court order that can halt commercial launch while the underlying patent dispute is resolved, even after FDA approval. If the court grants Janssen’s motion, Immgolis and Immgolis Intri could not be sold in the United States until the litigation concludes or the injunction is lifted, even though the FDA approval is final. If the court denies the motion, Accord and Bio-Thera can proceed with their planned Q4 2026 launch while litigation continues. The court’s decision on the preliminary injunction will depend on Janssen’s ability to show a likelihood of success on the merits of its patent claims and that irreparable harm would result from allowing the launch to proceed. Given that 17 patents are asserted, the litigation is likely to be complex and prolonged regardless of the preliminary injunction outcome.

    The Alvotech/Teva context: A competing golimumab biosimilar (AVT05, golimumab) developed by Alvotech and Teva received a Complete Response Letter from the FDA in November 2025 following manufacturing concerns at Alvotech’s facility in Reykjavik, Iceland. Alvotech planned resubmission in Q2 2026. If AVT05 is ultimately approved, it would be the second golimumab biosimilar and would add competitive pricing pressure to the market.

    What This Means for Patients on Simponi or Simponi Aria

    Should you switch right now?

    No. Immgolis and Immgolis Intri are approved but not yet commercially available. Accord BioPharma has stated a Q4 2026 launch target, which is subject to the litigation outcome. Patients currently stable on Simponi or Simponi Aria should remain on their current regimen until their rheumatologist initiates a conversation about any formulary change.

    What will change when these products launch?

    When Immgolis and Immgolis Intri become available, several things may happen depending on your insurance plan:

    • Your insurer may add one or both biosimilars to its preferred formulary tier, potentially lowering your copay if you switch
    • Your pharmacy may substitute the biosimilar for a Simponi or Simponi Aria prescription at the counter, given the interchangeable designation, and must notify you and your prescriber
    • Step therapy requirements could shift, with insurers potentially requiring biosimilar trial before covering the originator

    What to do if your pharmacist substitutes a biosimilar

    If your pharmacist substitutes Immgolis for your Simponi prescription or Immgolis Intri for your Simponi Aria prescription, they are required by law in most states to notify you of the substitution and to notify your prescriber. The FDA has determined these products are clinically interchangeable. If you have concerns about a substitution, you or your prescriber can request “dispense as written” on your prescription to prevent automatic substitution.

    What cannot be substituted for what

    Immgolis (subcutaneous) is interchangeable with Simponi, not with Simponi Aria. Immgolis Intri (intravenous) is interchangeable with Simponi Aria, not with Simponi. The two Immgolis products cannot be substituted for each other, because they have different routes of administration, doses, and indications.

    Additionally, Immgolis and Immgolis Intri do not yet carry indications for ankylosing spondylitis or psoriatic arthritis. Patients using Simponi for either of those conditions should discuss with their rheumatologist before any switch is considered.

    The Broader Context: The Simponi Market and TNF Inhibitor Biosimilars

    Simponi and Simponi Aria generated combined U.S. sales of approximately $1.19 to $1.2 billion in 2025, making golimumab one of the last major TNF inhibitors to face biosimilar competition. Adalimumab (Humira) now has more than a dozen approved biosimilars and has seen substantial price competition. Etanercept (Enbrel) and infliximab (Remicade) have also seen biosimilar market entry. Golimumab has remained relatively insulated until now.

    The arrival of interchangeable biosimilars is typically the moment at which meaningful price competition can begin, because interchangeability allows formulary switching at the pharmacy level without the prescriber friction that limits non-interchangeable biosimilars. Whether Immgolis and Immgolis Intri produce Simponi price reductions comparable to what adalimumab biosimilars achieved with Humira will depend on the litigation outcome, Accord’s pricing strategy, and the pace of formulary decisions by major pharmacy benefit managers.

    Patients with rheumatoid arthritis and ulcerative colitis who are currently priced out of golimumab therapy have the most to gain from effective biosimilar competition. For those on Simponi for ankylosing spondylitis or psoriatic arthritis, the current Immgolis approval does not directly apply, though the existence of approved biosimilars may influence Janssen’s own pricing decisions over time.

    For related HED coverage of the biosimilar market dynamics in other drug classes, see our post on PONLIMSI and why FDA biosimilar approvals do not automatically translate to patient savings and our post on interchangeable basal insulin biosimilars and what the approval of Langlara means for insulin access.

    Sources

    FDA approval announcement: FDA approves first interchangeable biosimilars to Simponi and Simponi Aria (golimumab) to treat rheumatoid arthritis and ulcerative colitis. FDA.gov. May 15, 2026.

    Accord BioPharma press release: FDA Approves IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI (golimumab-sldi), First Biosimilars to Simponi (golimumab) and Simponi Aria (golimumab); Accord BioPharma to Lead U.S. Commercialization. PRNewswire. May 18, 2026.

    Bio-Thera Solutions press release: Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi and Simponi Aria. BioSpace. May 18, 2026.

    Medscape clinical coverage: FDA Approves First Golimumab Biosimilars to Treat Rheumatoid Arthritis and Ulcerative Colitis. Medscape. May 18, 2026.

    BioPharm International: FDA Approves First Golimumab Biosimilars from Accord BioPharma. biopharminternational.com. May 2026.

    Drug Topics clinical summary: FDA Approves Golimumab-Sldi as First Biosimilar for Simponi. drugtopics.com. May 2026.

    Patent litigation (Big Molecule Watch): FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch. bigmoleculewatch.com. May 22, 2026.

    Janssen BPCIA complaint (Bloomberg Law): J&J’s Janssen Targets Accord Simponi Biosimilars in Patent Suit. bloomberglaw.com. March 2026.

    Accord/Bio-Thera IPRs: Accord and Bio-Thera File Four IPRs Challenging Janssen Simponi Patents. biologicshq.com. March 27, 2026.

    Pearce IP litigation summary: Bio-Thera/Accord BioPharma Secure First FDA Approval of Golimumab Biosimilars. pearceip.law. May 2026.

    Simponi reference FDA approval: FDA approves golimumab (Simponi). FDA.gov.

    Simponi Aria reference FDA approval: FDA approves golimumab (Simponi Aria). FDA.gov.

    Golimumab mechanism: Golimumab. StatPearls. NCBI.

    TNF-alpha biology: Tumor Necrosis Factor. StatPearls. NCBI.

    CRP reference: C-Reactive Protein. StatPearls. NCBI.

    BPCIA framework: Biosimilar Development, Review, and Approval. FDA.gov.

    FDA interchangeable biosimilars: Biosimilar and Interchangeable Products. FDA.gov.

    NIAMS RA overview: Rheumatoid Arthritis. niams.nih.gov.

    NIAMS ankylosing spondylitis: Ankylosing Spondylitis. niams.nih.gov.

    NIAMS psoriatic arthritis: Psoriatic Arthritis. niams.nih.gov.

    NIDDK ulcerative colitis: Ulcerative Colitis. niddk.nih.gov.

    TB testing before biologics: Testing for Latent TB Infection. CDC.

    Patient resources: Arthritis Foundation | Crohn’s and Colitis Foundation | NIAMS Rheumatoid Arthritis

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Immgolis and Immgolis Intri are FDA-approved but not yet commercially available; planned Q4 2026 launch is subject to ongoing patent litigation. Decisions about switching between golimumab products should be made in consultation with a qualified rheumatologist or gastroenterologist familiar with your complete treatment history and indication.
  • Your Asthma Is Still Not Controlled on Two Inhalers. The FDA Just Approved a Third Drug You Can Add Without Adding a Second Device.

    Your Asthma Is Still Not Controlled on Two Inhalers. The FDA Just Approved a Third Drug You Can Add Without Adding a Second Device.

    📌 The essentials On May 14, 2026, the FDA approved Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate, Chiesi USA), a single-inhaler triple combination therapy for the long-term maintenance treatment of asthma in adults. It is the first and currently only inhaled triple combination therapy approved in the United States for asthma that delivers all three drug classes, an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), in a single pressurized metered-dose inhaler. Indication: long-term maintenance treatment of asthma in adults. Not for children. Not for use as a rescue inhaler. Dosing: 2 inhalations twice daily (morning and evening), 4 total per day. Two strengths: 86 mcg/4.9 mcg/10.6 mcg and 172 mcg/4.9 mcg/10.6 mcg per actuation. The clinical basis: two Phase 3 randomized, double-blind, active-controlled trials, TRIMARAN and TRIGGER, enrolling 2,592 adults with uncontrolled asthma. Both trials showed statistically significant improvements in pre-dose FEV1 at 26 weeks compared with dual ICS/LABA therapy alone. TRIMARAN also showed a statistically significant 15% reduction in the rate of moderate and severe exacerbations. Critical safety note: Trimbow contains a LABA (formoterol). Do not use any other LABA or any other anticholinergic medication while taking Trimbow.

    Asthma affects approximately 27 million Americans and is a leading cause of emergency department visits, missed school and work days, and chronic respiratory morbidity. For most patients, the treatment goal is straightforward: control inflammation with an inhaled corticosteroid, open the airways with a bronchodilator, and live without symptoms. For many, that goal is achievable with a combination ICS/LABA inhaler.

    But a substantial proportion of patients, estimated at 5 to 10% of all asthma patients and sometimes characterized as moderate to severe uncontrolled asthma, do not achieve adequate control on dual ICS/LABA therapy even with appropriate adherence and technique. For these patients, the next therapeutic step has typically involved adding a long-acting muscarinic antagonist (LAMA), a third drug class that relaxes airway smooth muscle through a different mechanism than beta-agonists. Until now, adding a LAMA meant adding a separate inhaler, which adds complexity, cost, and another opportunity for missed or incorrect doses.

    On May 14, 2026, the FDA approved Trimbow, a single inhaler containing all three classes simultaneously. The clinical data supporting it has been in the literature since 2019, published in The Lancet. The U.S. approval now makes this approach officially available to American patients and prescribers.

    What Uncontrolled Asthma on ICS/LABA Looks Like and Why a Third Drug Class Helps

    To understand what Trimbow adds, it helps to understand the three drug classes it combines and why each contributes something the others cannot fully replace.

    Beclomethasone dipropionate: the ICS component

    Beclomethasone dipropionate (BDP) is a synthetic glucocorticoid that suppresses the airway inflammation that underlies asthma. Inflammation is the root cause of the chronic bronchial hyperreactivity that makes asthmatic airways prone to spasm, swelling, and mucus production. ICS therapy is the foundational treatment for persistent asthma because no bronchodilator, however effective at opening airways acutely, addresses the underlying inflammatory state. BDP is one of the most extensively studied and commonly used ICS agents. In Trimbow, it is formulated in an extrafine particle size (mass median aerodynamic diameter below 2 micrometers) that allows improved deposition in the small airways, a region of the lung that is a significant site of inflammation in asthma and that larger-particle formulations reach less effectively.

    Formoterol fumarate: the LABA component

    Formoterol fumarate is a long-acting beta2-agonist (LABA) that works by binding to beta2-adrenergic receptors on airway smooth muscle, causing relaxation and dilation. This bronchodilation reduces airway resistance and improves airflow. Unlike short-acting beta2-agonists (SABAs) such as albuterol, which last 4 to 6 hours and are used for quick relief, formoterol is designed for sustained bronchodilation over approximately 12 hours. It is taken twice daily as a maintenance medication, not for acute symptoms. Formoterol also has a relatively rapid onset compared to other LABAs, beginning to act within minutes of inhalation.

    An important safety note: LABAs, when used without an ICS, increase the risk of asthma-related hospitalizations and death. This risk drove FDA requirements that LABAs only be prescribed in combination with ICS for asthma. Trimbow contains both, so this risk is not present in the way it is with LABA-only products.

    Glycopyrrolate: the LAMA component

    Glycopyrrolate (also called glycopyrronium) is a long-acting muscarinic antagonist (LAMA) that blocks muscarinic receptors on airway smooth muscle and submucosal glands. Muscarinic receptors respond to acetylcholine, a neurotransmitter released by the parasympathetic nervous system. Parasympathetic stimulation causes bronchoconstriction and increased mucus secretion, both of which worsen airway obstruction in asthma. Glycopyrrolate blocks these effects, producing additional bronchodilation and reducing mucus production through a mechanism completely distinct from formoterol’s beta-agonist pathway.

    This mechanistic complementarity is the rationale for combining a LABA and a LAMA: they dilate airways through two separate receptor pathways, producing additive bronchodilation beyond what either achieves alone. In COPD, where LABA/LAMA combinations are well-established, this additive effect is substantial. In asthma, the role of LAMA therapy is newer and the evidence base is still evolving, which is what makes the TRIMARAN and TRIGGER trial data important.

    Why adding a LAMA to asthma therapy is different from COPD In COPD, LAMA therapy is foundational and often used as first-line bronchodilation, because the disease is primarily driven by fixed airflow limitation and parasympathetically mediated bronchoconstriction. In asthma, the primary problem is ICS-reversible inflammation with episodic bronchospasm, and the role of the parasympathetic nervous system is less dominant than in COPD. This is why LAMAs were not part of asthma therapy for many years: the theoretical rationale was weaker. The TRIMARAN and TRIGGER trials were specifically designed to test whether adding a LAMA to ICS/LABA in patients already failing dual therapy would produce meaningful additional benefit. The answer, at least for lung function and for severe exacerbations in TRIMARAN, was yes. The question of which patients benefit most, and how much, is one the subgroup analyses have tried to answer.

    The TRIMARAN and TRIGGER Trials: What the Evidence Actually Shows

    The FDA approval is based on two Phase 3 randomized, double-blind, active-controlled trials, both published in The Lancet in November 2019 and extensively analyzed in subsequent publications.

    Trial design

    Both trials enrolled adults with uncontrolled asthma, defined as:

    • Asthma Control Questionnaire-7 (ACQ-7) score of 1.5 or higher (indicating inadequate asthma control)
    • Pre-bronchodilator FEV1 below 80% of predicted normal (confirming measurable airflow limitation)
    • History of at least one moderate or severe asthma exacerbation in the prior year (establishing meaningful disease burden)
    • Current treatment with medium-dose ICS/LABA (TRIMARAN) or high-dose ICS/LABA (TRIGGER)

    TRIMARAN NCT02676076: enrolled 1,155 patients. Compared medium-strength BDP/FF/G (100 mcg/6 mcg/10 mcg per actuation) versus medium-strength BDP/FF (100 mcg/6 mcg) for 52 weeks.

    TRIGGER NCT02676089: enrolled 1,437 patients. Compared high-strength BDP/FF/G (200 mcg/6 mcg/10 mcg) versus high-strength BDP/FF (200 mcg/6 mcg), with an additional open-label arm receiving high-strength BDP/FF plus tiotropium (a separate LAMA) once daily, providing a comparison against adding a LAMA in a separate inhaler rather than a combined one.

    Co-primary endpoints for both trials were pre-dose FEV1 at week 26 and the rate of moderate and severe exacerbations over 52 weeks.

    Primary endpoint results

    OutcomeTRIMARAN (medium dose)TRIGGER (high dose)
    Improvement in pre-dose FEV1 at Week 26 (BDP/FF/G vs BDP/FF)+57 mL (95% CI 15 to 99; p=0.0080)+73 mL (95% CI 26 to 120; p=0.0025)
    Rate of moderate-to-severe exacerbations over 52 weeks (rate ratio vs BDP/FF)Rate ratio 0.85 (95% CI 0.73 to 0.99; p=0.033), 15% reductionRate ratio 0.88 (95% CI 0.75 to 1.03; p=0.11), 12% reduction, not statistically significant
    Patients experiencing moderate-to-severe exacerbations58.6% (BDP/FF/G) vs 66.0% (BDP/FF)56.6% (BDP/FF/G) vs 63.7% (BDP/FF)
    Patients experiencing severe exacerbations18.2% (BDP/FF/G) vs 22.4% (BDP/FF)Numerically reduced; statistically significant for severe exacerbations
    Tiotropium add-on vs BDP/FF/G (TRIGGER only)—No statistically significant differences between the combined inhaler and the separate LAMA arm

    Source: Virchow JC et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER). The Lancet. 2019;394(10210):1737-1749. doi:10.1016/S0140-6736(19)32028-9.

    The FEV1 improvements in both trials are statistically significant and, while modest in absolute terms (57 to 73 mL), are consistent with meaningful clinical benefit in a population where gains are incremental. The 15% reduction in moderate and severe exacerbation rate in TRIMARAN is the more clinically impactful finding: exacerbations are the main driver of asthma-related hospitalizations, emergency visits, oral corticosteroid courses, and lung function decline over time. Reducing exacerbations reduces downstream harm.

    The fact that TRIGGER’s exacerbation reduction did not reach statistical significance (p=0.11 for combined moderate and severe) is worth acknowledging honestly. However, the point estimate was similar to TRIMARAN (12% vs 15%), and the severe exacerbation data in TRIGGER was statistically significant. The likely explanation for the differing statistical outcomes is that TRIGGER enrolled patients on higher-dose ICS/LABA, who are by definition more disease-refractory, making further improvement harder to demonstrate and more heterogeneous.

    The TRIGGER tiotropium add-on arm is also clinically important. The three-way comparison showed no statistically significant difference in outcomes between the triple combination inhaler and adding tiotropium as a separate inhaler to ICS/LABA. This means Trimbow is not demonstrably superior to the established approach of adding a separate LAMA inhaler. What it offers is the same clinical effect in a single device rather than two, which is a convenience and adherence advantage rather than a pharmacological superiority.

    Remission-on-treatment analysis

    A post-hoc analysis published in the Journal of Allergy and Clinical Immunology (2025) evaluated whether triple therapy increased the proportion of patients achieving on-treatment remission, defined as no severe exacerbations and no systemic corticosteroid use over 52 weeks, plus ACQ-5 score below 1.5 at weeks 26, 40, and 52, plus stable or improved lung function. In TRIMARAN, 30.2% of patients on triple therapy met all remission criteria compared with 25.6% on dual therapy. This finding is exploratory and post-hoc, but it provides useful context for the meaningful goal of deep disease control rather than simply symptom reduction.

    The Extrafine Formulation: Why Particle Size Matters

    Trimbow is specifically described as an extrafine formulation, meaning the active ingredients are delivered in particles with a mass median aerodynamic diameter below 2 micrometers. This is smaller than standard inhaled corticosteroid particles, which typically have diameters of 2 to 5 micrometers.

    The significance of small-particle size relates to where in the lung the drug deposits. Larger particles tend to deposit in the central airways, the larger bronchi visible on bronchoscopy. Smaller particles travel further into the lung, reaching the small airways below 2 mm in diameter. In asthma, inflammation and airflow limitation are present throughout the bronchial tree, including in these small peripheral airways, and conventional larger-particle inhalers may not adequately treat this compartment.

    This is not a theoretical claim for Trimbow specifically: the TRIMARAN and TRIGGER trials were conducted with the extrafine formulation, and the results reflect its performance. Whether the extrafine delivery is responsible for a meaningful component of the observed benefit, or whether standard-particle LABA/LAMA/ICS would perform similarly, has not been tested head-to-head in asthma.

    Who Is Trimbow For? Patient Selection and the Treatment Hierarchy

    Trimbow is not a first-line therapy for asthma. It is indicated for adults with asthma that is not adequately controlled on existing treatment, specifically on medium or high-dose ICS/LABA combination therapy. The GINA (Global Initiative for Asthma) guidelines position LAMA add-on as a Step 4 to 5 consideration for patients with persistent symptoms or exacerbations on medium-to-high-dose ICS/LABA, which is exactly the population studied in TRIMARAN and TRIGGER.

    Trimbow is appropriate to consider for patients who:

    • Have documented uncontrolled asthma (frequent symptoms, reliever use, recent exacerbations, or reduced quality of life) despite adherent use of a medium or high-dose ICS/LABA inhaler
    • Have experienced at least one moderate or severe exacerbation in the past year
    • Have pre-bronchodilator FEV1 below 80% of predicted, indicating measurable airflow limitation
    • Are adults (Trimbow is not approved for children)

    Trimbow is not appropriate for patients who:

    • Need emergency or acute symptom relief (Trimbow is a maintenance inhaler, not a rescue inhaler; always carry albuterol or another SABA)
    • Are already using a separate LAMA inhaler (tiotropium, ipratropium, aclidinium, umeclidinium) or another LABA (salmeterol, vilanterol, indacaterol, olodaterol) — combining Trimbow with these creates duplicate drug class exposure with elevated risk of cardiovascular and anticholinergic side effects
    • Are children under 18
    • Have poorly controlled narrow-angle glaucoma or significant urinary retention from enlarged prostate, as the anticholinergic component can worsen both

    Safety: What Patients and Clinicians Need to Know

    The safety profile of Trimbow reflects the combined profile of its three components, each of which has decades of clinical experience in other products.

    The LABA safety warning

    LABAs carry a class-level FDA warning: when used without an ICS, they increase the risk of asthma-related death and hospitalization. This risk is resolved when LABAs are combined with an ICS, as they are in Trimbow. The warning is present on the label but not a contraindication for ICS/LABA combination use. It is the reason that LABAs should never be used as monotherapy in asthma.

    Serious risks requiring awareness

    • Oral thrush (oropharyngeal candidiasis): The most common ICS-related complication. Rinse and gargle with water after every use, without swallowing. This simple step significantly reduces the risk.
    • Adrenal insufficiency: In patients transitioning from oral or systemic corticosteroids to an ICS-containing inhaler, the adrenal glands may not immediately produce sufficient cortisol during physiological stress (illness, surgery, trauma). This risk is real during the transition period and requires gradual steroid tapering under medical supervision.
    • Paradoxical bronchospasm: Occasionally, an inhaled medication causes immediate airway tightening rather than opening. If this occurs, stop Trimbow and seek medical care immediately.
    • Cardiovascular effects: The beta-agonist and anticholinergic components can increase heart rate and blood pressure. Monitor patients with underlying cardiovascular conditions.
    • Glaucoma and urinary retention: The anticholinergic component (glycopyrrolate) increases intraocular pressure and can worsen urinary retention from enlarged prostate. Patients with these conditions need evaluation before starting Trimbow, and regular eye exams are recommended during use.
    • Osteoporosis: Long-term ICS use at higher doses contributes to bone density reduction. Assess bone health, particularly in patients with other osteoporosis risk factors.
    • Metabolic effects: Elevated blood glucose (particularly in patients with diabetes or at risk for it) and low potassium are possible with LABA therapy.

    Common side effects

    Bronchitis, upper respiratory infections, hoarseness, mouth and throat discomfort, back pain, and muscle spasms were among the most commonly reported adverse events in clinical trials. Oral hoarseness specifically is related to vocal cord effects of the corticosteroid and can often be reduced by rinsing after use and using a spacer device.

    Dosing, Administration, and Storage

    FeatureDetails
    Dose2 inhalations twice daily (morning and evening), 4 total puffs per day
    Available strengths86 mcg/4.9 mcg/10.6 mcg (medium) and 172 mcg/4.9 mcg/10.6 mcg (high) per actuation
    Device typePressurized metered-dose inhaler (pMDI)
    Spacer useRecommended to improve lung deposition and reduce oropharyngeal deposition
    Rinse mouthAfter every use, with water, without swallowing
    Storage before first useRefrigerate at 36°F to 46°F (2°C to 8°C)
    Storage after first useBelow 77°F (25°C) for a maximum of 2 months; discard after 2 months or when dose counter reaches zero
    Do notFreeze; use near heat or open flame; pierce the canister
    Missed doseTake as soon as remembered on the same day; skip if it is already the next day; never take more than 4 puffs per day

    If you have previously used a beclomethasone-containing inhaler from a different manufacturer, ask your prescriber about the effective dose. Trimbow’s extrafine formulation may deliver equivalent clinical effect at a lower stated dose than some other BDP-containing products due to improved small airway deposition.

    Where Trimbow Fits in the U.S. Asthma Treatment Landscape

    Trimbow is the first single-inhaler ICS/LABA/LAMA approved for asthma in the United States. There are existing single-inhaler triple combinations approved for COPD, including Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) and Trelegy Ellipta (fluticasone/umeclidinium/vilanterol), but Trimbow is the first such combination with an asthma-specific approval in the U.S.

    Adding a LAMA to ICS/LABA therapy in asthma is already supported by GINA guidelines and the American Thoracic Society/European Respiratory Society guidelines for patients with uncontrolled moderate to severe asthma. What Trimbow provides is the ability to implement this strategy in a single inhaler, which has meaningful practical implications for patients managing multiple devices.

    A note on biologic therapy for severe asthma For patients with severe, refractory asthma and elevated eosinophils or IgE, biologic therapies targeting the type 2 inflammatory pathway are an important consideration alongside or instead of triple inhaled therapy. These include dupilumab (Dupixent), mepolizumab (Nucala), benralizumab (Fasenra), omalizumab (Xolair), and others. These are injected subcutaneous therapies with their own clinical trial programs and indications. Whether triple inhaled therapy or biologic therapy is the appropriate next step for a given patient depends on asthma phenotype, eosinophil count, allergy status, exacerbation history, and other clinical factors best discussed with a pulmonologist or allergist. Trimbow and biologic therapy are not mutually exclusive; some patients may use both.

    For Patients: What to Discuss With Your Doctor

    If your asthma is still not controlled despite consistent use of a combination ICS/LABA inhaler, Trimbow may be worth discussing with your pulmonologist or allergist. The relevant questions are:

    • Does my current asthma control score indicate uncontrolled disease despite adherent dual therapy?
    • Have I had exacerbations requiring oral steroids or emergency care in the past year?
    • Is my pre-bronchodilator FEV1 below normal, suggesting persistent airflow limitation?
    • Do I have any contraindications to a LAMA (glaucoma, significant urinary retention, active narrow-angle glaucoma)?
    • Am I currently on a separate LAMA or LABA that would need to be discontinued before starting Trimbow?

    For general asthma management resources, the American Lung Association and the Asthma and Allergy Foundation of America (AAFA) maintain patient-facing guides on asthma treatment, inhaler technique, and finding specialist care. The GINA Pocket Guide for Patients provides evidence-based guidance on asthma management that patients can review with their healthcare providers.

    Sources

    FDA approval news: FDA Approves Trimbow (beclomethasone/formoterol/glycopyrrolate) Inhaler for the Maintenance Treatment of Asthma. Drugs.com. May 14, 2026.

    Trimbow prescribing information: Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate) Prescribing Information. Chiesi USA. 2026.

    Drugs.com drug information: Trimbow: Uses, Dosage, Side Effects and Warnings. drugs.com.

    TRIMARAN and TRIGGER primary Lancet publication: Virchow JC et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. The Lancet. 2019;394(10210):1737-1749. doi:10.1016/S0140-6736(19)32028-9.

    TRIMARAN trial registration: NCT02676076. ClinicalTrials.gov.

    TRIGGER trial registration: NCT02676089. ClinicalTrials.gov.

    Remission-on-treatment analysis: Post-hoc analysis of TRIMARAN and TRIGGER: achieving asthma remission with BDP/FF/GB. Journal of Allergy and Clinical Immunology. 2025.

    Subgroup determinants analysis: Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respiratory Research. 2020. PMC7597025.

    Triple therapy review (extrafine formulation): Ridolo E et al. Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide in the treatment of asthma: a review. Therapeutic Advances in Respiratory Disease. 2025.

    Small airways disease in asthma: Small Airways Disease in Asthma. PMC6560600.

    LABA FDA safety communication: FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications (LABAs). FDA.gov.

    NHLBI asthma overview: Asthma. National Heart, Lung, and Blood Institute.

    GINA guidelines: Global Initiative for Asthma (GINA) Reports. ginasthma.org.

    Beclomethasone dipropionate: Beclomethasone Dipropionate. StatPearls. NCBI.

    Formoterol fumarate: Formoterol Fumarate. StatPearls. NCBI.

    Glycopyrrolate/glycopyrronium: Glycopyrrolate. StatPearls. NCBI.

    ACQ-7 instrument: Asthma Control Questionnaire validation. PMC4799806.

    Patient resources: American Lung Association | Asthma and Allergy Foundation of America | GINA Guidelines

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Asthma management decisions, including changes to inhaler therapy, should be made in consultation with a qualified pulmonologist, allergist, or primary care provider familiar with your individual asthma history and current treatment.
  • High Blood Pressure That Won’t Budge on Multiple Medications Just Got Its First New Drug Class in Decades. Here Is What Baxfendy Is and What the BaxHTN Data Shows.

    High Blood Pressure That Won’t Budge on Multiple Medications Just Got Its First New Drug Class in Decades. Here Is What Baxfendy Is and What the BaxHTN Data Shows.

    📌 The essentials On May 18, 2026, the FDA approved Baxfendy (baxdrostat, AstraZeneca) as the first and only aldosterone synthase inhibitor (ASI) for the treatment of hypertension. Baxfendy is the first drug in an entirely new pharmacological class to be approved for high blood pressure in decades. Indication: in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents. This is an add-on therapy, not a replacement for existing medications. Dosing: 2 mg orally once daily (recommended dose); 1 mg once daily for patients at increased risk of hyperkalemia or hyponatremia. Available: expected early June 2026. The clinical basis: Phase 3 BaxHTN trial (NCT06034743), published in the New England Journal of Medicine on August 30, 2025, enrolling 796 patients across 214 sites in 29 countries. Key result: placebo-adjusted systolic blood pressure reduction of 9.8 mmHg (2 mg dose) and 8.7 mmHg (1 mg dose) at 12 weeks (p less than 0.001 for both). Key safety warnings: hyperkalemia (elevated potassium) and hyponatremia (low sodium). Monitor electrolytes. Important caveat: the approval is based on blood pressure reduction as a surrogate endpoint, not on direct cardiovascular outcomes data. A cardiovascular outcomes trial is expected to follow.

    Hypertension affects an estimated 1.4 billion people worldwide and approximately 119 million adults in the United States. It is the single largest modifiable risk factor for stroke, myocardial infarction, heart failure, and chronic kidney disease. And yet, despite a treatment landscape that includes a dozen established drug classes and hundreds of individual medications, approximately 50% of patients on multiple antihypertensive treatments still do not have their blood pressure adequately controlled.

    The patients in that 50% are not failing treatment through non-compliance alone. Many of them have a biological reason their blood pressure is hard to control, namely elevated or dysregulated aldosterone, a hormone that promotes sodium and water retention and raises blood pressure through mechanisms that existing drug classes do not directly address. Recognizing that aldosterone dysregulation is far more prevalent in difficult-to-control hypertension than previously understood is part of what makes Baxfendy’s approval a meaningful scientific development rather than just an incremental addition to a crowded market.

    On May 18, 2026, the FDA approved Baxfendy (baxdrostat), the first aldosterone synthase inhibitor ever approved for hypertension. It targets the production of aldosterone itself, a mechanistic approach no approved drug has taken before in this indication.

    What Aldosterone Is and Why Inhibiting Its Production Is a New Idea

    To understand what makes Baxfendy mechanistically distinct, it helps to understand both what aldosterone does and why existing treatments have not addressed its overproduction directly.

    Aldosterone is a steroid hormone produced by the adrenal glands, specifically in a region called the zona glomerulosa. Its primary role is to regulate sodium and potassium balance in the kidneys. When aldosterone is elevated, the kidneys retain more sodium and water, increasing blood volume and raising blood pressure. Aldosterone also promotes potassium excretion, which is why elevated aldosterone is often associated with low potassium levels.

    The enzyme responsible for producing aldosterone in the zona glomerulosa is called aldosterone synthase (CYP11B2). There is a closely related enzyme, cortisol synthase (CYP11B1), that makes cortisol in a neighboring region of the adrenal gland. Earlier attempts to develop aldosterone synthase inhibitors failed because they could not distinguish between CYP11B2 and CYP11B1 well enough: blocking both suppresses not only aldosterone but also cortisol, which is essential for the stress response and metabolic regulation. The side effects of cortisol suppression at therapeutic doses were unacceptable.

    Baxdrostat is designed to solve this problem. It is described as a highly selective inhibitor of CYP11B2 that spares CYP11B1. In the BaxHTN trial, cortisol levels were monitored and remained stable, with no clinically meaningful cortisol suppression detected.

    How existing drug classes compare mechanistically

    Existing antihypertensive classes target aldosterone’s effects downstream rather than its production:

    • ACE inhibitors and ARBs block the renin-angiotensin-aldosterone system (RAAS) at earlier steps, reducing angiotensin II signaling that drives aldosterone secretion. But in many patients, aldosterone eventually “escapes” this inhibition through angiotensin-independent pathways.
    • Mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone block the aldosterone receptor in the kidney rather than reducing aldosterone itself. They are effective in resistant hypertension but carry a significant hyperkalemia risk, limiting their use in patients with chronic kidney disease.
    • Diuretics reduce blood volume directly, addressing one consequence of aldosterone excess without reducing aldosterone levels.

    Baxdrostat is the first approved drug to work at the top of this pathway, reducing aldosterone production in the adrenal gland before it reaches the circulation. Whether this upstream approach ultimately produces better clinical outcomes than MRAs in head-to-head comparison is not yet established by trial data.

    The BaxHTN Trial: Design and Full Results

    Trial design

    The BaxHTN Phase 3 trial (NCT06034743) was a multinational, randomized, double-blind, placebo-controlled study conducted at 214 clinical sites across 29 countries. Results were presented at the European Society of Cardiology Congress 2025 in Madrid in August 2025 and simultaneously published in the New England Journal of Medicine.

    Eligibility:

    • Seated systolic blood pressure (SBP) of 140 mmHg or higher and less than 170 mmHg
    • Receiving stable treatment with at least 2 antihypertensive medications of different classes, one of which was a diuretic (uncontrolled hypertension group), or at least 3 antihypertensive medications including a diuretic (resistant hypertension group)
    • Estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m² or higher
    • Serum potassium within acceptable range at baseline

    Enrollment: 796 patients total across uncontrolled and resistant hypertension subgroups.

    Design structure: After a placebo run-in period, the trial had four sequential phases: a 12-week double-blind, placebo-controlled period (the primary analysis period); a 12-week open-label extension; an 8-week randomized withdrawal period to assess persistence of effect; and a 20-week open-label safety assessment.

    Primary endpoint results

    Outcome at 12 weeksBaxdrostat 2 mgBaxdrostat 1 mgPlacebo
    Mean seated SBP reduction from baseline15.7 mmHg (95% CI 13.7 to 17.6)14.6 mmHgApproximately 5.9 mmHg
    Placebo-adjusted SBP reduction9.8 mmHg (95% CI 7.0 to 12.6)8.7 mmHg (95% CI 6.0 to 11.4)Reference
    p-valuep less than 0.001p less than 0.001—
    Cortisol levelsNo clinically meaningful changeNo clinically meaningful change—
    Aldosterone reductionSignificantSignificantNo change

    Source: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine. Published August 30, 2025. doi:10.1056/NEJMoa2507109. BaxHTN NCT06034743.

    The 9.8 mmHg placebo-adjusted SBP reduction at the 2 mg dose is clinically significant in context. Epidemiological data consistently show that a 10 mmHg reduction in systolic blood pressure is associated with approximately a 20% lower risk of serious cardiovascular events. In a population already on two or more antihypertensive medications, achieving nearly 10 mmHg additional reduction from one add-on pill is a meaningful result.

    The randomized withdrawal period confirmed that blood pressure rose when baxdrostat was stopped and returned to target when it was reintroduced, confirming that the drug’s effect was causal rather than incidental.

    The Bax24 trial: 24-hour ambulatory blood pressure

    A separate Phase 3 study, Bax24 (NCT06168409), evaluated baxdrostat specifically in resistant hypertension using 24-hour ambulatory blood pressure monitoring (ABPM) rather than seated office measurements. Ambulatory blood pressure is considered a more reliable predictor of cardiovascular outcomes than clinic-based readings because it captures average pressure across the full daily cycle including nighttime.

    Presented at the American Heart Association Scientific Sessions 2025 and published in The Lancet in March 2026, Bax24 showed a placebo-adjusted reduction of 14.0 mmHg in 24-hour average systolic blood pressure (p less than 0.0001) in patients with resistant hypertension. Nighttime systolic blood pressure was reduced by 13.9 mmHg (placebo-adjusted). Notably, 71% of baxdrostat-treated patients achieved a 24-hour average SBP below 130 mmHg compared with 17% of placebo-treated patients.

    The Bax24 findings are not part of the current FDA approval label, but they are relevant context for understanding how comprehensively baxdrostat controls blood pressure across the full daily cycle in the most difficult-to-treat patients.

    The uncontrolled vs. resistant hypertension distinction The BaxHTN trial enrolled two overlapping but distinct populations. Uncontrolled hypertension is defined as blood pressure that remains above target despite the use of two antihypertensive medications. Resistant hypertension is a more stringent category: blood pressure that remains above target despite three antihypertensive agents including a diuretic, or that requires four or more agents to achieve control. Resistant hypertension is estimated to affect 10 to 15% of all hypertension patients and carries a substantially higher risk of end-organ damage, including left ventricular hypertrophy, kidney disease, and stroke. Both groups were included in BaxHTN because elevated aldosterone has been implicated in both, though the biological rationale is strongest in resistant hypertension where aldosterone escape from RAAS therapy is well-documented.

    Safety: What the Label Covers

    Baxdrostat was generally well tolerated in the BaxHTN trial, with no unexpected safety findings reported. The most clinically significant warnings in the prescribing information are:

    Hyperkalemia (elevated potassium): The most important class-related concern. Aldosterone promotes potassium excretion in the kidney. Inhibiting aldosterone synthesis reduces that excretion, which can raise serum potassium. The risk is greatest in patients with chronic kidney disease or those on other drugs that raise potassium, including ACE inhibitors, ARBs, MRAs, and potassium-sparing diuretics. The 1 mg starting dose is specifically recommended for patients at increased risk of hyperkalemia. Baseline and periodic electrolyte monitoring is essential.

    Hyponatremia (low sodium): Less common than hyperkalemia but present in the trial data. Monitor sodium, particularly in older patients or those at risk for volume-related sodium shifts.

    Adrenal function: Despite the selective mechanism, monitoring for signs of adrenal insufficiency is prudent in patients undergoing physiological stress such as illness or surgery, given the proximity of the drug’s mechanism to cortisol synthesis.

    Common adverse events from the trial included headache, dizziness, and fatigue. Rates of these were generally comparable between baxdrostat and placebo.

    Drug interactions to know: Because baxdrostat reduces aldosterone, its combination with MRAs (spironolactone, eplerenone, finerenone) produces additive aldosterone-lowering effects and substantially increases the risk of hyperkalemia. The prescribing information addresses this interaction specifically. Clinicians should review the full prescribing information before initiating.

    What This Means for Patients and Clinicians

    Who is this drug for?

    Baxfendy is approved as add-on therapy for adults with hypertension that is not adequately controlled on other agents. The typical candidate based on the BaxHTN enrollment criteria is a patient who:

    • Has systolic blood pressure of 140 mmHg or higher despite being on at least 2 established antihypertensive medications
    • Is already taking a diuretic as part of their regimen
    • Has adequate kidney function (eGFR of 45 or higher)
    • Does not have a potassium level that contraindicates further aldosterone suppression

    It is not approved as monotherapy or as initial hypertension treatment. Patients already well-controlled on existing medications have no indication to switch.

    Who should discuss this with their cardiologist or hypertension specialist?

    Patients with documented uncontrolled or resistant hypertension who have cycled through ACE inhibitors, ARBs, calcium channel blockers, and diuretics without achieving target blood pressure are the population this drug was designed for. The mechanism is specifically compelling for patients suspected to have elevated aldosterone as a driver, including those with primary aldosteronism or confirmed aldosterone excess, though the approval does not require this testing.

    What is still unknown

    The current FDA approval is based on blood pressure reduction as a surrogate endpoint, not on direct demonstration that baxdrostat reduces heart attacks, strokes, kidney disease progression, or death. In antihypertensive drug development, this is standard and accepted: the FDA has long approved blood pressure medications based on surrogate blood pressure endpoints given the overwhelming prior evidence that blood pressure reduction reduces cardiovascular events across drug classes.

    That said, a cardiovascular outcomes trial is expected to follow. The results of that trial will be important for fully establishing Baxfendy’s place in the treatment hierarchy and for understanding whether aldosterone-specific lowering produces benefits beyond what is predicted by the blood pressure reduction alone. AstraZeneca has also announced trials in primary aldosteronism, chronic kidney disease with hypertension, and heart failure prevention, as well as a combination development program with dapagliflozin.

    The Bigger Picture: A New Mechanism in a Disease That Has Needed One

    Hypertension’s pharmacological armamentarium has not seen a genuinely new mechanism in a long time. Most drug classes currently prescribed for hypertension were developed between the 1950s and 1990s. Baxfendy’s approval is notable precisely because it represents a new biological angle on a very old problem.

    The recognition that aldosterone dysregulation is far more prevalent in treatment-resistant hypertension than the classical primary aldosteronism diagnosis would suggest has been building in the cardiology literature for more than a decade. Studies using more sensitive aldosterone assays have found that a significant proportion of patients with resistant hypertension have inappropriately elevated aldosterone relative to their sodium and volume status, even without the discrete aldosterone-secreting adenomas that define classical primary aldosteronism. BaxHTN’s results are consistent with this evolving understanding: the magnitude of blood pressure reduction seen suggests that the drug is addressing a real and prevalent biological driver of difficult-to-control hypertension, not just an edge-case mechanism.

    For patients whose blood pressure has resisted years of medication escalation, having a drug that works through a pathway none of their existing medications addresses is clinically meaningful, independent of where it eventually lands in outcome trials.

    For related coverage of advances in cardiovascular and metabolic drug development, see our post on the first generic dapagliflozin, which covers the SGLT2 inhibitor class and its now-expanding role from blood sugar management to cardiovascular and kidney protection, and our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes.

    Sources

    AstraZeneca FDA approval press release: BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension. AstraZeneca. May 18, 2026.

    AstraZeneca US press release: FDA Approves Baxfendy (baxdrostat) as the First Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension. businesswire.com. May 18, 2026.

    BaxHTN primary NEJM publication: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. New England Journal of Medicine. August 30, 2025. doi:10.1056/NEJMoa2507109.

    BaxHTN trial registration: NCT06034743. ClinicalTrials.gov.

    Bax24 primary Lancet publication: Azizi M et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24). The Lancet. 2026 Mar 7;407(10532):988-999.

    Bax24 trial registration: NCT06168409. ClinicalTrials.gov.

    BaxHTN Phase 3 design paper: Flack JM et al. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertension Research. 2025. doi:10.1038/s41440-025-02297-7.

    BioPharma Dive approval coverage: AstraZeneca wins US approval for Baxfendy hypertension drug. biopharmadive.com. May 18, 2026.

    Cardiology Advisor approval coverage: Baxfendy Earns FDA Nod as First-in-Class Hypertension Treatment. thecardiologyadvisor.com. May 2026.

    PharmExec coverage: FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry. pharmexec.com. May 2026.

    HCPLive approval coverage: FDA Approves Baxdrostat for Uncontrolled Hypertension on Background Therapy. hcplive.com. May 2026.

    ESC Congress 2025 presentation: BaxHTN top-line data presented at ESC Congress 2025, Madrid, August 30, 2025.

    AHA Scientific Sessions 2025 (Bax24): Bax24 Phase III trial full results presented at AHA Scientific Sessions 2025.

    Drugs.com approval news: FDA Approves Baxfendy (baxdrostat) as the First Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension. drugs.com. May 18, 2026.

    Aldosterone biology: Aldosterone. StatPearls. NCBI.

    Aldosterone synthase selectivity: CYP11B2 and CYP11B1 selectivity in aldosterone synthase inhibitors. PMC6116014.

    ACE inhibitors and ARBs: ACE Inhibitors. StatPearls. NCBI.

    MRAs in hypertension: Mineralocorticoid Receptor Antagonists. StatPearls. NCBI.

    Diuretics in hypertension: Diuretics. StatPearls. NCBI.

    NHLBI hypertension overview: High Blood Pressure. National Heart, Lung, and Blood Institute.

    Patient resources: American Heart Association: High Blood Pressure | National Hypertension Control Initiative | AstraZeneca Baxfendy information

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Baxfendy is approved as add-on therapy and should only be initiated and monitored by a qualified healthcare provider. Blood pressure management requires individualized care; do not stop or change antihypertensive medications without consulting your prescriber.
  • A Child’s Legs Grow Stiffer Every Year. For Decades, Nothing Could Stop It. The FDA Just Approved the First Drug That Addresses Why.

    A Child’s Legs Grow Stiffer Every Year. For Decades, Nothing Could Stop It. The FDA Just Approved the First Drug That Addresses Why.

    📌  The essentials Drug: Loargys (pegzilarginase-nbln) — a PEGylated recombinant human arginase-1 enzyme. FDA approval type: Accelerated approval, February 23, 2026. Based on reduction of plasma arginine as a surrogate endpoint. Continued approval may depend on confirmatory trial results. Developer: Immedica Pharma (Stockholm/Chicago). Indication: Treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. What makes it first-in-class: First and only FDA-approved therapy proven to lower arginine levels in ARG1-D. Prior management was symptomatic only — dietary restriction and ammonia scavengers. Neither addressed endogenous arginine production. Key trial results (PEACE, n=32): 90.5% of pegzilarginase patients normalized plasma arginine at 24 weeks vs 0% on placebo. Mean plasma arginine reduced from 354 to 86 μmol/L (72% reduction, p<0.0001). Administration: Intravenous infusion once weekly, administered in a healthcare setting. Subcutaneous administration was offered in the long-term extension. Critical warning: Boxed warning for life-threatening hypersensitivity reactions including anaphylaxis. Requires administration under direct healthcare supervision with emergency support available. Availability: Estimated available in the U.S. from April 2026. Patient support: There for Rare program (Immedica).

    The parents of a child with Arginase 1 Deficiency learn quickly that the disease does not announce itself with a dramatic crisis. There is no sudden collapse. There is no dramatic fever. Instead, something subtler and harder to name: the child who was walking begins to walk differently. The legs become stiffer. The gait changes. Developmental milestones come later than expected, or not at all. The child who could run begins to struggle with stairs.

    Many of these families spent years before diagnosis being told it was cerebral palsy, or hereditary spastic paraplegia, or developmental delay without a clear cause. The correct diagnosis, when it finally came, offered a name for what was happening but not a way to stop it. Management meant strict dietary protein restriction, which is genuinely difficult to maintain in a young child, and ammonia scavenger drugs that addressed one downstream consequence of the disease without touching the core problem: too much arginine in the blood, accumulating every day, slowly damaging the nervous system.

    On February 23, 2026, the FDA granted accelerated approval to Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in patients aged 2 and older with Arginase 1 Deficiency. It is the first drug approved that directly addresses the underlying biochemical defect — replacing the missing enzyme, lowering arginine, and in long-term studies, improving the very spasticity that defines this disease.

    What Is Arginase 1 Deficiency and Why Does Arginine Damage the Nervous System?

    The urea cycle is the biochemical pathway the liver uses to convert ammonia, a toxic byproduct of protein metabolism, into urea for excretion. The cycle involves eight enzymes working in sequence. Arginase 1 is the final enzyme in the cycle: it cleaves the amino acid arginine into urea and ornithine, the last step before ammonia-derived waste leaves the body.

    In ARG1-D, both copies of the ARG1 gene are mutated (autosomal recessive inheritance), and arginase-1 enzyme activity is severely reduced or absent. Arginine, which cannot be cleared, accumulates persistently in the blood and cerebrospinal fluid. Normal plasma arginine is below 100 micromolar (μmol/L). Patients with ARG1-D typically present with levels of 300 to 500 μmol/L. It is this chronic arginine elevation, and the accumulation of arginine’s toxic metabolites including guanidino compounds, that causes progressive neurological damage.

    Unlike most other urea cycle disorders, ARG1-D is not primarily characterized by hyperammonemia crises. Ammonia levels are often near-normal, because the blocked urea cycle step is at the end of the pathway. This is part of why the disease is different from other urea cycle disorders and why managing ammonia does not meaningfully control ARG1-D.

    How ARG1-D typically presents and why it is so often misdiagnosed Clinical manifestations in ARG1-D are typically absent in the newborn period and early infancy, despite the metabolic defect being present from birth. Symptoms usually first appear between ages 1 and 3 years. The most common initial presentation is spasticity of the lower limbs, followed by developmental delay and loss of previously acquired motor milestones. Because spasticity and gait abnormalities in young children are common features of cerebral palsy and hereditary spastic paraplegia, ARG1-D is frequently misdiagnosed as one of these conditions. A systematic review found that diagnostic delays are common, driven by limited disease awareness, the absence of hyperammonemic crises (which would more immediately suggest a urea cycle disorder), and inconsistent availability of newborn screening programs that could detect elevated arginine at birth. ARG1-D is listed on the Recommended Uniform Screening Panel (RUSP) for U.S. newborn screening, but inclusion varies by state, and the sensitivity of screening for ARG1-D using standard amino acid profiling has been debated. For families who receive a diagnosis late, the neurological damage that has already accumulated during the years of missed diagnosis is not fully reversible. This is the clinical argument for early diagnosis and early treatment.

    How Loargys Works: Replacing the Enzyme, Not Just Managing Its Absence

    Pegzilarginase is a recombinant human arginase-1 enzyme produced using genetic engineering, then modified by attaching polyethylene glycol (PEG) chains to its surface. This PEGylation serves two purposes: it extends the enzyme’s half-life in the bloodstream, making once-weekly dosing sufficient, and it reduces immunogenicity, lowering the risk that the immune system will produce antibodies that neutralize the enzyme.

    When pegzilarginase is administered intravenously, it acts as an exogenous source of the arginase-1 activity the patient’s own cells cannot provide. It circulates in the blood and catalyzes the conversion of arginine to ornithine and urea, just as endogenous arginase-1 would in a person without the deficiency. This directly lowers plasma arginine levels toward the normal range.

    This mechanism addresses the fundamental limitation of dietary protein restriction: even with strict dietary control, the body continues to produce arginine endogenously through the first part of the urea cycle. Restricting dietary protein reduces the amount of arginine coming in from food, but it cannot stop the liver from producing arginine from within. Pegzilarginase clears both sources.

    The PEACE Trial: What the Clinical Data Shows

    Trial design

    The PEACE trial (NCT03921541) was a Phase 3, randomized, double-blind, placebo-controlled study conducted at 19 sites in 7 countries (United States, Canada, United Kingdom, Austria, France, Germany, and Italy). It enrolled 32 patients aged 2 years and older with genetically confirmed ARG1-D. Patients were randomized 2:1 to receive IV pegzilarginase (n=21) or matched placebo (n=11) once weekly for 24 weeks. Patients continued their existing individualized disease management (dietary restriction, ammonia scavengers) throughout.

    A sample size of 32 in a randomized controlled trial is small by conventional standards. It is large for a disease with a median prevalence of 1 in 1,000,000. The PEACE trial enrolled what was, at the time, the largest prospectively studied ARG1-D cohort ever assembled, and it is the first randomized, blinded, placebo-controlled clinical trial ever conducted in this disease.

    Primary endpoint: plasma arginine reduction

    MeasurePegzilarginasePlacebo
    Plasma arginine at baseline354.0 μmol/L (geometric mean)464.7 μmol/L
    Plasma arginine at week 2486.4 μmol/L426.6 μmol/L
    Mean percent reduction72% (p<0.0001)No meaningful change
    Mean absolute reduction−312 μmol/L (95% CI −384 to −239)—
    Patients reaching target (<200 μmol/L)90.5%0%
    Patients reaching normal levels (<100 μmol/L)90.5%0%

    Source: PEACE trial, eClinicalMedicine (Lancet). 2024;68:102400. doi:10.1016/j.eclinm.2023.102400. NCT03921541.

    The 90.5% versus 0% normalization rate is the most arresting number in the entire dataset. No patient on placebo brought their plasma arginine into the normal range; nearly all patients on pegzilarginase did. The clinical trial design, in which dietary management continued in both arms, means this difference is attributable specifically to the enzyme replacement therapy, not to dietary changes.

    Mobility outcomes: secondary endpoints and long-term extension data

    The primary endpoint of the PEACE trial was plasma arginine reduction, the surrogate measure on which accelerated approval was granted. Secondary endpoints examined functional mobility using validated instruments: the Gross Motor Function Measure (GMFM-D and GMFM-E subscales), timed walk tests, and the 6-minute walk test. These endpoints showed a positive trend in the pegzilarginase arm during the 24-week trial period.

    The more clinically compelling functional data comes from the long-term extension (LTE) studies, which followed patients receiving pegzilarginase for up to 5 years. Published in 2025, these combined results from Study 102A (n=14, up to 5 years) and the PEACE LTE (n=31, up to 3 years) showed:

    • Spasticity improved in 84% of patients, as measured by the Modified Ashworth Scale (MAS).
    • 12 patients achieved MAS 0, meaning no detectable spasticity at all.
    • Six-minute walk test (6MWT) distances improved across the cohort, reflecting real-world functional mobility gains.
    • Gross Motor Function Measure scores improved in the D and E subscales (standing and walking/running/jumping), which are the most clinically relevant for patients with ARG1-D.
    • Plasma arginine remained suppressed at normal or near-normal levels throughout the extension period.
    • An Italian real-world case series also documented that when treatment was interrupted for 13 months after the trial concluded, arginine levels returned and spasticity worsened; when treatment was restarted, benefits resumed. This discontinuation-rechallenge observation is the strongest indirect evidence that the biochemical normalization drives the functional improvement.
    Why this is accelerated approval and what that means The FDA approved Loargys under the accelerated approval pathway, which allows earlier access to drugs for serious conditions based on a surrogate endpoint reasonably likely to predict clinical benefit. For Loargys, the surrogate is plasma arginine reduction. The rationale is well-established in the ARG1-D literature: persistent arginine elevation is the proximal driver of neurological damage in this disease. Normalizing arginine is mechanistically sound as a predictor of clinical benefit. Continued approval may depend on confirmatory trial results demonstrating actual clinical benefit such as improved functional outcomes. The long-term extension data described above, while not the confirmatory trial, provides the strongest available evidence that arginine normalization does translate into meaningful spasticity reduction and mobility improvement. For families: accelerated approval means the FDA has determined the drug works on a meaningful surrogate and that the benefit outweighs the risk given the severity of the disease. It does not mean clinical benefit is fully confirmed. The full evidence picture will emerge from the confirmatory studies.

    Safety: The Anaphylaxis Warning That Requires In-Clinic Administration

    Boxed warning: hypersensitivity reactions including anaphylaxis

    Loargys carries a boxed warning for life-threatening hypersensitivity reactions, including anaphylaxis. This risk is the primary reason the drug must be administered under direct supervision in a healthcare setting with emergency support immediately available. Reactions can occur during or after infusion. For this reason, Loargys is not a self-administered home therapy — every dose requires a scheduled clinic or infusion center visit.

    Signs of a hypersensitivity reaction that require immediate intervention include hives, difficulty breathing, swelling of the face or throat, rapid or irregular heartbeat, dizziness, and loss of consciousness. Patients and families should be counseled on these symptoms before each infusion.

    Other adverse reactions

    The most common adverse reactions in the PEACE trial were vomiting, pyrexia (fever), infusion-associated reactions, and constipation. These are manageable in most cases. The real-world Italian case series, following three pediatric patients over years of treatment, did not report serious safety events apart from infusion reactions. The prescribing information also includes a precaution for embryo-fetal toxicity, relevant for patients of reproductive age.

    Practical Details: Dosing, Administration, and Patient Support

    FeatureDetails
    RouteIntravenous infusion (30 minutes)
    FrequencyOnce weekly
    SettingHealthcare setting with direct supervision; emergency support required
    Available formulationsSingle-dose vials: 2 mg/0.4 mL and 5 mg/1 mL
    Subcutaneous optionAvailable in long-term extension phase; ask treating metabolic specialist about current access
    Used alongsideDietary protein restriction (required); ammonia scavengers if applicable
    AvailabilityEstimated available in U.S. from April 2026
    Patient supportThere for Rare program (Immedica): financial assistance and nonmedical education support
    ContraindicationsKnown hypersensitivity to pegzilarginase or excipients
    Pediatric useApproved from age 2 years; most clinical trial participants were pediatric or young adults

    What This Means for Families Affected by ARG1-D

    For a disease affecting roughly 1 in 1,000,000 people, ARG1-D has generated a disproportionate amount of research attention over the past decade, driven substantially by patient advocacy. The Arginase 1 Deficiency Foundation, established by families directly affected by the disease, has been one of the forces accelerating clinical development and raising the standard of care expectations for this patient community.

    The clinical significance of this approval should be understood in its proper context. Most patients diagnosed with ARG1-D today are children or young adults who have already accumulated some neurological damage before treatment can begin, because diagnosis often comes late. Loargys does not reverse established neurological damage. What the long-term extension data shows is that it can halt or reduce ongoing spasticity progression and improve functional mobility in patients who begin treatment. The most meaningful benefit likely comes with early treatment, before accumulated damage is severe.

    For newly diagnosed patients identified through newborn screening or early clinical presentation, Loargys represents the possibility of intervening before significant neurological damage accumulates. For older patients who have been managing on dietary restriction and ammonia scavengers alone, it represents the first drug that can actually bring arginine to normal levels and the only approved therapy with evidence of functional benefit.

    The weekly infusion requirement is a real burden for families, many of whom already manage complex dietary protocols and multiple specialist appointments. The availability of subcutaneous administration in the extension period, if it eventually becomes part of the approved label, would substantially reduce that burden. This is worth monitoring as post-marketing data accumulates.

    Resources for families and clinicians

    For families navigating an ARG1-D diagnosis, the Arginase 1 Deficiency Foundation (a1d.org) provides patient and family support resources, clinical trial information, and a community of families with direct experience of this disease. The National Urea Cycle Disorders Foundation (nucdf.org) covers the full spectrum of urea cycle disorders and maintains a specialist referral directory. For Loargys access and patient support, the There for Rare program is available through immedicaus.com.

    Sources

    FDA accelerated approval announcement: FDA grants accelerated approval to pegzilarginase-nbln (Loargys) for treatment of hyperargininemia in patients with ARG1-D. FDA.gov. February 23, 2026.

    Immedica press release: U.S. FDA has granted accelerated approval of Loargys (pegzilarginase-nbln) for treatment of hyperargininemia in patients 2 years and older with Arginase 1 Deficiency. Immedica Pharma. February 23, 2026.

    Endocrinology Advisor: FDA Grants Accelerated Approval to Loargys for Arginase 1 Deficiency. endocrinologyadvisor.com. February 25, 2026.

    Drugs.com history: Loargys (pegzilarginase-nbln) FDA Approval History. drugs.com.

    PEACE trial primary publication (eClinicalMedicine): Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. eClinicalMedicine (The Lancet). 2024;68:102400. doi:10.1016/j.eclinm.2023.102400. PMC10825663.

    Long-term extension study: Long-Term Efficacy and Tolerability of Pegzilarginase in Arginase 1 Deficiency: Results of Two International Multicentre Open-Label Extension Studies. PubMed PMID 40714964.

    Italian real-world case series (MDPI): Pegzilarginase in Arginase 1 Deficiency: Clinical and Biochemical Effects of Treatment Initiation, Discontinuation and Re-Initiation. MDPI Children. 2026;13(5):610.

    ARG1-D systematic review (prevalence/diagnosis): Epidemiology, methods of diagnosis, and clinical management of patients with ARG1-D: A systematic review. PubMed PMID 36049366.

    Natural history systematic review: Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports. JIMD Reports. PMC9259395.

    Misdiagnosis/clinical review (PMC): Arginase 1 deficiency: a treatable form of spastic paraplegia. PMC12394256.

    Trial registration: PEACE: A Phase 3 Study of Pegzilarginase in Patients With Arginase 1 Deficiency. NCT03921541. clinicaltrials.gov.

    Patient resources: Arginase 1 Deficiency Foundation: a1d.org; National Urea Cycle Disorders Foundation: nucdf.org; Immedica patient support: immedicaus.com

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Loargys is approved under the accelerated approval pathway, and continued approval may depend on confirmatory trial results. Treatment decisions for ARG1-D should be made in consultation with a metabolic specialist or biochemical geneticist experienced in urea cycle disorders.
  • Enhertu Is Now FDA-Approved for HER2-Positive Early Breast Cancer Before and After Surgery. Here Is What the DESTINY-Breast11 and DESTINY-Breast05 Data Shows.

    Enhertu Is Now FDA-Approved for HER2-Positive Early Breast Cancer Before and After Surgery. Here Is What the DESTINY-Breast11 and DESTINY-Breast05 Data Shows.

    ✅ Updated May 19, 2026: FDA Approval Confirmed On May 15, 2026, the FDA approved two new indications for Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd) in adults with HER2-positive early-stage breast cancer. This post has been updated throughout to reflect both approvals. For related coverage of Enhertu’s approved indications in metastatic HER2-positive and HER2-low breast cancer, and how this new approval extends Enhertu into the curative-intent setting, see our companion post on Dato-DXd in triple-negative breast cancer for context on the broader ADC landscape.
    📌 The essentials: Two approvals, two different clinical situations Indication 1: Neoadjuvant (before surgery) FDA approved Enhertu followed by THP (taxane, trastuzumab, pertuzumab) for adults with HER2-positive (IHC 3+ or ISH+) stage II or III breast cancer before surgery. Dose: 5.4 mg/kg IV every 3 weeks for 4 cycles, then THP for 4 cycles, then surgery. Clinical basis: DESTINY-Breast11 (NCT05113251): pCR rate 67.3% with T-DXd plus THP versus 56.3% with standard anthracycline-based ddAC-THP (absolute improvement +11.2%; p=0.003). Indication 2: Adjuvant (after surgery, for residual disease) FDA approved Enhertu for adults with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. Dose: 5.4 mg/kg IV every 3 weeks for a maximum of 14 cycles. Clinical basis: DESTINY-Breast05 (NCT04622319): T-DXd reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 (Kadcyla) (HR 0.47; 95% CI 0.34 to 0.66; p less than 0.0001). Three-year invasive disease-free survival (iDFS): 92.4% versus 83.7%. Key safety note: the label carries a boxed warning for interstitial lung disease (ILD) and pneumonitis. ILD rate was 4.4% in DESTINY-Breast11 and approximately 10% in DESTINY-Breast05. Additional warnings: neutropenia and left ventricular dysfunction.

    When a woman is diagnosed with HER2-positive breast cancer, the weeks between diagnosis and surgery are not a waiting period. They are a treatment window, one that oncologists have spent decades trying to use more aggressively and more effectively. The drugs given before surgery, in the neoadjuvant setting, have the opportunity to shrink the tumor, treat any cancer that may have spread to lymph nodes or beyond, and ideally produce an outcome that changes what surgery looks like and what long-term prognosis looks like.

    That neoadjuvant window has been anchored to anthracycline-containing chemotherapy regimens for more than a decade. Anthracyclines work, but they carry a burden: cardiac toxicity, hematologic toxicity, significant treatment interruptions. The question oncologists have been asking is whether something better is now available.

    On May 18, 2026, the FDA is expected to rule on exactly that question. The drug at the center of the decision is Enhertu (trastuzumab deruxtecan, T-DXd), an antibody-drug conjugate that has already redefined outcomes in metastatic breast cancer. The clinical trial behind the application, DESTINY-Breast11, is the first positive global registrational trial for a new neoadjuvant agent in HER2-positive early breast cancer in over a decade. The data makes a compelling case. Understanding what it actually shows, and what it doesn’t yet tell us, is what this post is for.

    HER2-Positive Breast Cancer and the Neoadjuvant Treatment Window

    HER2 (human epidermal growth factor receptor 2) is a protein that promotes cell growth. In approximately 15 to 20% of breast cancers, the HER2 gene is amplified, producing too many HER2 receptors on tumor cell surfaces and driving aggressive cancer growth. HER2-positive breast cancer tends to grow faster than hormone receptor-positive cancer but is also more sensitive to HER2-targeted therapies.

    Neoadjuvant therapy refers to systemic treatment given before surgery. This is different from adjuvant therapy, which is given after surgery to reduce recurrence risk. In HER2-positive early breast cancer, neoadjuvant treatment serves several purposes:

    • It may downstage the tumor, reducing its size and lymph node involvement, potentially enabling less extensive surgery
    • It allows oncologists to observe the tumor’s response to treatment in real time
    • It provides important prognostic information that guides post-surgery treatment decisions
    • Most critically: it creates the opportunity for pathologic complete response, the most meaningful outcome measure in this setting
    What is a pathologic complete response (pCR) and why does it matter? A pathologic complete response (pCR) means that when the removed tumor and lymph nodes are examined under a microscope after surgery, no viable invasive cancer cells are found. In DESTINY-Breast11, the pCR definition used was ypT0/is ypN0, meaning no residual invasive cancer in the breast (with allowance for non-invasive in-situ disease) and no cancer in the lymph nodes. pCR is one of the most important prognostic markers in HER2-positive breast cancer. Patients who achieve pCR have substantially lower rates of cancer recurrence and significantly better long-term survival than those with residual disease. The relationship between pCR and survival is why the FDA accepts it as a surrogate endpoint for approval in the neoadjuvant setting. The clinical decision implications extend beyond prognosis. Patients who achieve pCR typically continue with standard adjuvant therapy and may be candidates for less extensive surgery. Patients who do NOT achieve pCR are typically offered additional targeted therapy after surgery (currently, T-DM1/Kadcyla is the standard for residual HER2+ disease) to try to reduce their recurrence risk. Understanding pCR rates is therefore both a survival question and a treatment-planning question.

    What Enhertu Is and How It Works

    Enhertu (trastuzumab deruxtecan, T-DXd) is an antibody-drug conjugate (ADC), a category of targeted therapy that links a cancer-targeting antibody to a chemotherapy payload. The antibody component is trastuzumab, which has been a cornerstone of HER2-positive breast cancer treatment for decades. The payload is deruxtecan, a topoisomerase I inhibitor chemotherapy. The linker between them is designed to be stable in the bloodstream but cleaved inside tumor cells.

    The mechanism creates a guided delivery system. Trastuzumab finds tumor cells expressing HER2 on their surface and binds to them. The ADC is then internalized into the cell, where the linker is cleaved and the deruxtecan payload is released directly inside the cancer cell, causing it to die. A key additional property of T-DXd’s payload is what’s called a bystander effect: some of the released chemotherapy can diffuse into neighboring cancer cells, including those that may not strongly express HER2. This may help explain T-DXd’s activity even in heterogeneous tumors.

    T-DXd already has FDA approvals for:

    If the May 18 decision is favorable, the neoadjuvant HER2-positive early breast cancer indication would be added to this list. For context on how ADC technology works in a related breast cancer setting, see our detailed coverage of Dato-DXd and TROPION-Breast02 in triple-negative breast cancer.

    The DESTINY-Breast11 Trial: Design and Results

    Design

    DESTINY-Breast11 (NCT05113251) was a global, multicenter, randomized, open-label Phase 3 trial conducted at 147 sites across 18 countries. It enrolled adults with previously untreated, high-risk HER2-positive early breast cancer, defined as tumors that were either T3 or larger with any nodal status, or any T stage with N1 to N3 nodal involvement (node-positive disease), including inflammatory breast cancer. The HER2-positive definition required either IHC 3+ or positive in situ hybridization. Patients were randomized in a 1:1:1 design across three arms:

    • T-DXd monotherapy arm: T-DXd 5.4 mg/kg every 3 weeks for 8 cycles (n=286), closed early
    • T-DXd-THP arm: T-DXd 5.4 mg/kg every 3 weeks for 4 cycles, then paclitaxel plus trastuzumab plus pertuzumab (THP) for 4 cycles (n=321)
    • ddAC-THP (control arm): Dose-dense doxorubicin plus cyclophosphamide every 2 weeks for 4 cycles, then THP for 4 cycles (n=320)

    The T-DXd monotherapy arm was closed early in March 2024, following an Independent Data Monitoring Committee recommendation based on lower pCR rates than the combination arms and low likelihood of demonstrating superiority. This was a pre-specified adaptive design decision, not a safety signal.

    Primary endpoint: pCR results

    OutcomeT-DXd plus THP (n=321)ddAC plus THP (n=320)
    pCR rate (ypT0/is ypN0)67.3%56.3%
    Absolute difference in pCR+11.0 percentage points—
    p-value0.003—
    Patients proceeding to surgery97.2%Comparable
    EFS HR (immature, 4.5% events)0.56 (95% CI 0.26 to 1.17)Reference

    Source: Harbeck N et al. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3. Presented at ESMO Congress 2025, Berlin. Abstract 291O.

    The 11-point improvement in pCR rate is clinically meaningful by any standard in this disease. To put it in context: with existing standard-of-care regimens, pCR rates in high-risk HER2-positive disease range from approximately 39 to 64% depending on population characteristics and regimen. The DESTINY-Breast11 control arm (56.3%) sits in the middle of that range, reflecting an appropriately representative benchmark. The T-DXd-THP arm’s 67.3% is at the top of and above that historical range.

    The benefit was consistent across pre-specified subgroups, including both hormone receptor-positive and hormone receptor-negative tumors, an important finding because HER2+/HR+ tumors historically have lower pCR rates and represent a more challenging treatment population.

    What about long-term survival?

    The EFS (event-free survival) hazard ratio of 0.56 suggests a 44% reduction in the rate of recurrence or death events in favor of T-DXd-THP numerically. However, EFS data maturity was only 4.5% at the time of the analysis, meaning very few events had occurred. The confidence interval (0.26 to 1.17) crosses 1.0, meaning the survival benefit is directionally promising but not yet statistically confirmed.

    This is expected and appropriate for a neoadjuvant trial in early-stage cancer: these patients were diagnosed at a potentially curable stage, and survival events take years to accumulate. The FDA’s precedent for accepting pCR as a surrogate endpoint in the neoadjuvant setting means approval does not require mature survival data. More mature EFS and overall survival data from DESTINY-Breast11 will emerge over subsequent years and will be critical for confirming the long-term value of the pCR benefit.

    Safety: Better Tolerability Than the Current Standard, With One Key Signal to Monitor

    One of the most striking findings in DESTINY-Breast11 is not the efficacy. It is the safety comparison. The T-DXd-THP arm had substantially fewer severe adverse events than the anthracycline-based control.

    Safety MetricT-DXd plus THPddAC plus THP
    Grade 3 or higher adverse events37.5%55.8%
    Serious adverse events10.6%20.2%
    Treatment interruptions37.8%54.5%
    Left ventricular dysfunction (all grade)1.3%6.1%
    ILD/pneumonitis (all grade)4.4%5.1%
    Grade 3/4 ILD events15
    Grade 5 (fatal) ILD events11
    Treatment-related deaths (all causes)1 (0.3%)2 (0.6%)
    Most common Grade 3 or higher AENeutropenia (13.8%)Hematologic toxicity predominant
    Fatigue (all grade)41.3%54.8%

    The cardiac finding warrants specific emphasis. Doxorubicin (the “A” in AC chemotherapy) is associated with dose-dependent cardiotoxicity, including cardiomyopathy and heart failure, that can emerge during treatment and persist or worsen years later. The 6.1% rate of left ventricular dysfunction in the control arm versus 1.3% in the T-DXd-THP arm represents a clinically important difference in a population that will be living with the long-term consequences of treatment for decades.

    The ILD signal: the key safety consideration for T-DXd Interstitial lung disease (ILD), inflammation and scarring of lung tissue, is the most important safety concern with T-DXd across all its indications. In DESTINY-Breast11, the all-grade ILD rate was 4.4% in the T-DXd-THP arm and 5.1% in the control arm, which are comparable. Most events were Grade 1 or 2 and manageable with dose modification and corticosteroids. However, there was one Grade 5 (fatal) ILD event in each arm, with the independent adjudication committee attributing one death in the T-DXd-THP arm to drug-related pneumonitis. This is not a reason to avoid the drug; one in each arm is a roughly comparable rate at this sample size. But ILD monitoring is a critical clinical requirement for T-DXd in practice. Current guidance requires baseline pulmonary assessment before starting T-DXd, prompt evaluation of any new or worsening respiratory symptoms (dyspnea, cough, fever), immediate T-DXd interruption if ILD is suspected, and corticosteroid treatment for confirmed cases. Providers switching to this regimen must be familiar with ILD surveillance protocols.

    What This Means for Patients Navigating Treatment Right Now

    If you have been diagnosed with HER2-positive breast cancer at stage II or III and are at the stage of discussing neoadjuvant treatment options with your oncologist, this FDA decision is directly relevant to your care.

    If the FDA approves on May 18

    • T-DXd followed by THP would become an FDA-approved option for high-risk (stage II/III) HER2-positive early breast cancer, specifically for patients with node-positive disease (N1 to N3) or large tumors (T3 or larger).
    • Your oncologist may recommend this regimen over the current anthracycline-based standard, particularly if your tumor characteristics suggest high risk and you have cardiovascular risk factors that make doxorubicin’s cardiac effects a concern.
    • The treatment involves 4 cycles of T-DXd (intravenous, every 3 weeks), followed by 4 cycles of paclitaxel plus trastuzumab plus pertuzumab, then surgery. Post-surgery treatment depends on whether you achieved pCR.
    • If you have already started a neoadjuvant regimen: do not switch without discussion with your oncologist. Mid-treatment changes are complex and require careful individual assessment.

    The treatment pathway after surgery

    pCR does not mean treatment is finished. Patients who achieve pCR after neoadjuvant therapy typically continue with adjuvant trastuzumab with or without pertuzumab, and those with HR+ disease also receive endocrine therapy. Patients who do NOT achieve pCR currently receive adjuvant ado-trastuzumab emtansine (T-DM1/Kadcyla) to address the residual disease that proved resistant to neoadjuvant treatment.

    A higher pCR rate means more patients entering that post-surgery phase in the most favorable prognostic position. For patients who still have residual disease, the adjuvant escalation pathway remains unchanged by this approval.

    For related context on ADC mechanisms and how different ADCs work across breast cancer subtypes, see our post on vepdegestrant and the PROTAC mechanism in ESR1-mutated ER+ breast cancer and our analysis of Dato-DXd in triple-negative breast cancer.

    Reading This Honestly: Context and Limitations

    Survival data is immature

    At 4.5% EFS maturity, we do not yet have confirmatory evidence that the pCR improvement translates into longer survival. The FDA’s precedent allows pCR as a surrogate, and the EFS directional signal (HR 0.56) is encouraging, but it is not yet proven. Patients and oncologists making decisions now are extrapolating from a strong surrogate, not from confirmed survival benefit. The maturing EFS and OS data from DESTINY-Breast11 will be the most important data to watch over the next several years.

    Representation limitations

    The published trial report specifically notes under-representation of Black or African American patients. This is a meaningful limitation in a disease where Black women are more likely to be diagnosed with aggressive subtypes and at advanced stages, and where outcomes disparities are well documented. Whether the pCR and safety results generalize fully to this population requires additional study and real-world evidence.

    The monotherapy arm closed early

    T-DXd monotherapy (without the THP sequence) achieved pCR rates of 43 to 51%, which is numerically inferior to both the combination arm and the control arm. The IDMC closed enrollment in that arm based on this finding. The approved regimen, if cleared, will be T-DXd followed by THP, not T-DXd alone. This distinction matters for clinical implementation.

    What Happens on and After May 18

    The PDUFA date is May 18, 2026. This is the deadline by which the FDA must complete its review. Decisions can come on or before this date.

    If approved, T-DXd followed by THP would immediately be available to prescribers as the first ADC-based neoadjuvant regimen for HER2-positive early breast cancer. NCCN guideline updates and payer coverage decisions typically follow relatively quickly for priority FDA approvals, though individual insurance authorization timelines vary.

    China has already approved this regimen based on the same DESTINY-Breast11 data. The European Medicines Agency review is ongoing. Regulatory validation across multiple agencies, if it follows, will strengthen the evidence base further.

    We will update this post when the FDA’s ruling is announced.

    Are you or a family member navigating a HER2-positive breast cancer diagnosis?

    Treatment decisions in early breast cancer are among the most consequential and time-sensitive in oncology. If you have been recently diagnosed with HER2-positive stage II or III breast cancer, the most important step is consultation with a breast oncologist at a cancer center with expertise in HER2-directed therapies and access to current clinical trial data. The NCI-Designated Cancer Centers directory maintains a searchable list of specialized breast oncology programs. Susan G. Komen and the Metastatic Breast Cancer Alliance maintain patient navigation resources. We will continue tracking the FDA’s decision and the maturing DESTINY-Breast11 survival data as both become available.

    Sources

    Primary trial publication: Harbeck N et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3

    PubMed: Harbeck N et al. DESTINY-Breast11. PubMed. PMID: 41130363.

    ESMO 2025 abstract: Harbeck N et al. DESTINY-Breast11: Neoadjuvant T-DXd alone or followed by THP vs SOC for high-risk HER2+ eBC. ESMO Congress 2025. Abstract 291O.

    DESTINY-Breast11 trial registration: NCT05113251. ClinicalTrials.gov.

    AstraZeneca/Daiichi Sankyo press release: Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients in DESTINY-Breast11 Phase III trial. astrazeneca.com. October 18, 2025.

    Targeted Oncology trial coverage: DESTINY-Breast11: Neoadjuvant T-DXd/THP Improves pCR in High-Risk HER2+ BC. targetedonc.com. October 2025.

    FDA surrogate endpoint resource: Surrogate Endpoint Resources for Drug and Biologic Development. FDA.gov.

    T-DM1 FDA approval: FDA approves ado-trastuzumab emtansine for HER2-positive breast cancer. FDA.gov.

    Patient resources: NCI Cancer Center directory | Susan G. Komen | MBC Alliance | NCCN Breast Cancer Guidelines

    Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about breast cancer treatment, including neoadjuvant therapy, should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, tumor characteristics, and health status.
  • The First BCL-2 Inhibitor Specifically Approved for Mantle Cell Lymphoma Just Received FDA Clearance. Here Is What the Data Shows.

    The First BCL-2 Inhibitor Specifically Approved for Mantle Cell Lymphoma Just Received FDA Clearance. Here Is What the Data Shows.

    📌  The essentials Drug: Beqalzi (sonrotoclax) — a next-generation, highly selective BCL-2 inhibitor. FDA approval type: Accelerated approval on May 13, 2026. Continued approval may depend on confirmatory clinical trial results. Developer: BeOne Medicines USA, Inc. (formerly BeiGene). Indication: Adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. What makes it first-in-class: First and only BCL-2 inhibitor specifically approved for MCL. Venetoclax (Venclexta) is approved for CLL and AML but not MCL. Key trial results (BGB-11417-201, n=103): ORR 52% (95% CI 42–62%), median duration of response 15.8 months, median time to response 1.9 months. Dosing: Oral tablet, once daily with food, following a 4-week dose ramp-up schedule. Target dose: 320 mg once daily. Critical warning: Tumor lysis syndrome (TLS) — potentially life-threatening. Requires risk assessment, prophylaxis, and close monitoring throughout the ramp-up phase. Regulatory designations: Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review. Reviewed under Project Orbis.

    Mantle cell lymphoma does not follow the forgiving course of many lymphoma subtypes. It is aggressive. It responds to first-line therapy in many patients, but it almost always comes back. After a first relapse on BTK inhibitor therapy, which has been the most important treatment advance in MCL over the past decade, options narrow considerably. Response rates with available agents are often modest. Duration of response can be brief. A population of patients with limited alternatives and deteriorating disease has been waiting for something new to try.

    On May 13, 2026, the FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory MCL after at least two prior lines of therapy including a BTK inhibitor. Beqalzi is a BCL-2 inhibitor, and it is the first drug in that class specifically approved for mantle cell lymphoma. The pivotal trial in 103 patients showed a 52% overall response rate and a median duration of response of 15.8 months, with a notably high response rate in TP53-mutant patients who typically fare poorly with existing options.

    Mantle Cell Lymphoma: Why Post-BTK Relapse Is Such a Difficult Problem

    Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma that originates in the mantle zone of the lymph node. It accounts for approximately 5% of non-Hodgkin lymphoma cases globally, with roughly 3,300 new diagnoses annually in the United States. The median age at diagnosis is approximately 65, and the disease is more common in men.

    MCL is characterized biologically by the t(11;14) chromosomal translocation, which places the CCND1 gene encoding cyclin D1 under the control of an immunoglobulin heavy chain promoter, driving overexpression of cyclin D1 and uncontrolled cell proliferation. Most MCL tumors also dysregulate the BCL-2 anti-apoptotic pathway, which helps cancer cells survive even when they should die. These two biological features, the proliferative driver and the survival mechanism, are both targets for therapy.

    BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) transformed the treatment of MCL at first and second relapse, producing high response rates in the 70-80% range. But responses are not permanent. Most patients eventually progress on BTK inhibitor therapy. At that point, the disease has developed resistance mechanisms, the patient has typically accumulated treatment-related organ stress, and available next-line options have produced response rates in the 20-40% range with short durations.

    TP53 mutations: the highest-risk subgroup in MCL TP53 encodes p53, the tumor suppressor protein that normally triggers cell death when DNA damage occurs. TP53 mutations are present in approximately 20–30% of MCL patients and are strongly associated with chemotherapy resistance, shorter remission durations, and worse overall survival. Patients with TP53-mutant MCL represent one of the highest-unmet-need populations in hematologic oncology. Standard chemotherapy regimens, which work partly through DNA damage that requires functional p53 to trigger apoptosis, are less effective when p53 is mutated. In the BGB-11417-201 trial supporting Beqalzi’s approval, the TP53-mutant subgroup achieved an ORR of 59.1%, numerically higher than the 52% overall population response rate. This is the opposite of what is typically seen with chemotherapy-based regimens in this subgroup, and it supports the mechanistic hypothesis that BCL-2 inhibition can bypass p53-dependent pathways to induce cancer cell death.

    How BCL-2 Inhibition Works and What Makes Sonrotoclax Different from Venetoclax

    BCL-2 (B-cell lymphoma 2) is a protein that promotes cell survival by blocking apoptosis, the programmed cell death process that the body uses to eliminate damaged, aged, or abnormal cells. In normal cells, BCL-2 is part of a balanced system of pro- and anti-apoptotic proteins. In many B-cell malignancies, BCL-2 is overexpressed, tipping the balance toward survival and allowing cancer cells to accumulate rather than die.

    BCL-2 inhibitors work by occupying the BH3-binding groove of the BCL-2 protein and displacing the pro-apoptotic proteins it normally sequesters. When these pro-apoptotic proteins are released, they activate the mitochondrial apoptosis cascade, triggering cell death. This mechanism is independent of TP53 function, which explains why BCL-2 inhibitors can be active in TP53-mutant tumors that resist DNA-damaging chemotherapy.

    Sonrotoclax versus venetoclax

    Venetoclax (Venclexta) is the established BCL-2 inhibitor in the market, approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It has been used off-label in MCL with modest activity. Sonrotoclax was engineered with greater potency and selectivity for BCL-2 compared to venetoclax, targeting BCL-2 more precisely while having less activity against the related BCL-XL protein.

    FeatureSonrotoclax (Beqalzi)Venetoclax (Venclexta)
    BCL-2 selectivityHigher selectivity for BCL-2; reduced BCL-XL activityBCL-2 selective; BCL-XL activity also noted
    FDA-approved for MCLYes — May 13, 2026 (accelerated)No — approved for CLL and AML only
    Approved indicationsR/R MCL after ≥2 lines including BTK inhibitorCLL (with obinutuzumab or ibrutinib), R/R AML (with azacitidine or decitabine)
    Target dose320 mg once daily (after 4-week ramp-up)400 mg once daily (after 5-week ramp-up for CLL)
    Tumor lysis syndrome riskYes — requires ramp-up and prophylaxisYes — requires ramp-up and prophylaxis
    RouteOral, once daily with foodOral, once daily with food

    The BGB-11417-201 Trial: Design and Results

    Trial design

    BGB-11417-201 (NCT05471843) is a single-arm, multicenter, open-label Phase 1/2 trial. Part 1 established the safety, tolerability, and recommended Phase 2 dose (RP2D) of sonrotoclax through dose escalation. No dose-limiting toxicities were observed during this phase, and 320 mg once daily was identified as the RP2D. Part 2 evaluated sonrotoclax at the 320 mg RP2D following a 4-week dose ramp-up schedule in patients with relapsed or refractory MCL.

    Eligibility for the efficacy-evaluable population required: histologically confirmed MCL, at least one prior anti-CD20-based therapy, at least one prior BTK inhibitor, ECOG performance status 0-2, adequate organ function, and no prior BCL-2 inhibitor therapy.

    Efficacy results

    EndpointResult
    Study population (Part 2)103 adults with R/R MCL; median age 68; all received prior anti-CD20 and BTK inhibitor
    Prior lines of therapy (median)3 (range 2–9)
    Overall response rate (ORR)52% (95% CI 42–62%; 1-sided p<0.0001)
    Complete response (CR) rate15.5% (95% CI 9.1–24.0%)
    Partial response (PR) rate36.9%
    Median time to first response1.9 months (range 1.6–6.2 months)
    Median duration of response (DOR)15.8 months (95% CI 7.4 months to not estimable)
    Median follow-up (efficacy analysis)11.9 months (per IRC) / 14.2 months (per Targeted Oncology)
    TP53-mutant subgroup ORR59.1%
    Assessment methodIndependent review committee (IRC) using Lugano criteria

    Source: FDA press release May 13, 2026. AJMC, ASCO Post, CancerNetwork, Targeted Oncology. BGB-11417-201, NCT05471843.

    A 52% ORR in a heavily pre-treated population, many of whom had BTK inhibitor-resistant disease after a median of three prior lines of therapy, is a meaningful result. The 15.8-month median DOR is also notable in a disease where post-BTK responses often last only a few months. The upper bound of the DOR confidence interval (not estimable) at a median follow-up of approximately 12 months suggests that a proportion of responses were still ongoing at the time of analysis.

    The TP53-mutant subgroup ORR of 59.1% is the most clinically significant finding for oncologists. Standard chemotherapy regimens are typically less effective in TP53-mutant MCL, and a response rate numerically higher in this subgroup than in the overall population suggests that BCL-2 inhibition may offer the most value precisely where current options are least effective.

    What accelerated approval means for this drug The FDA’s accelerated approval pathway allows earlier approval of drugs for serious conditions based on a surrogate endpoint (in this case, ORR and DOR) that is reasonably likely to predict clinical benefit, while requiring the sponsor to conduct confirmatory trials demonstrating actual clinical benefit such as overall survival. For Beqalzi, continued approval may depend on the results of confirmatory studies. BeOne Medicines is conducting a broader clinical program for sonrotoclax, including combination studies with BTK inhibitors (notably zanubrutinib, also a BeOne Medicine product) in MCL and other B-cell malignancies. If those studies demonstrate clinical benefit, the accelerated approval pathway to full approval becomes available. For patients with relapsed or refractory MCL who have exhausted prior lines of therapy, accelerated approval provides access to an investigational drug that has demonstrated meaningful activity now, rather than waiting for the confirmatory trial to complete. This is the intended purpose of the pathway for serious, life-threatening conditions.

    Safety: The TLS Warning That Requires Proactive Management

    Tumor lysis syndrome: the primary safety concern

    Tumor lysis syndrome is the most serious safety concern for Beqalzi, shared with venetoclax and other potent agents that rapidly kill large numbers of cancer cells. When cancer cells die quickly, they release their contents into the bloodstream: potassium, phosphate, nucleic acids, and uric acid. The kidneys may not be able to clear this influx quickly enough, leading to a metabolic emergency that can cause kidney failure, life-threatening cardiac arrhythmias, seizures, and death.

    Beqalzi’s prescribing information requires the following TLS management steps:

    • Pre-treatment risk assessment: Evaluate the patient’s baseline risk of TLS based on tumor bulk, renal function, and uric acid levels before starting Beqalzi.
    • Prophylactic hydration: Patients should drink 6 to 8 glasses (approximately 1.5 to 2 liters) of water daily starting 1 to 2 days before the first dose, on the day of the first dose, on any day the dose is increased, and when restarting treatment.
    • Anti-hyperuricemic agents: Healthcare providers may prescribe allopurinol or rasburicase before and during the dose ramp-up to reduce uric acid levels.
    • Blood monitoring: Blood tests for TLS markers (potassium, phosphate, uric acid, creatinine) are required before and during treatment, especially during the 4-week ramp-up.
    • 4-week ramp-up schedule: Doses are increased stepwise over 4 weeks to reach the 320 mg target dose, reducing the rate of cell death at any one time and lowering TLS risk. Strong CYP3A inhibitors are contraindicated during the ramp-up phase as they increase sonrotoclax exposure.

    Other important safety findings from the trial

    Serious adverse reactions occurred in 37% of patients in the trial, with pneumonia the most common serious adverse reaction at 10%. Grade 3 or 4 laboratory abnormalities occurring in at least 15% of patients included decreased lymphocyte counts and decreased neutrophil counts. The most common adverse reactions overall were pneumonia, fatigue, edema, diarrhea, and upper respiratory tract infection.

    The prescribing information also carries warnings for serious infections (including fatal infections) and neutropenia, both of which require monitoring. Patients on Beqalzi who develop fever, chills, or other signs of infection should contact their oncology team promptly.

    Beqalzi carries an embryo-fetal toxicity warning. Women of childbearing potential and male patients with female partners who could become pregnant must use effective contraception during treatment and for one week after the last dose.

    Dosing and Administration: The 4-Week Ramp-Up Schedule

    Ramp-up weekDaily doseKey requirement
    Week 1 (days 1–7)20 mg once dailyTLS monitoring; avoid strong CYP3A inhibitors
    Week 2 (days 8–14)80 mg once dailyTLS monitoring; hydration continued
    Week 3 (days 15–21)160 mg once dailyBlood tests for TLS markers
    Week 4 (days 22–28)240 mg once dailyContinue monitoring
    Week 5 onward320 mg once dailyTarget dose reached; once-daily dosing with food continues

    Beqalzi tablets are available in four strengths (1 mg, 5 mg, 20 mg, and 80 mg) to allow precise dosing throughout the ramp-up schedule. All doses should be taken with food. If a dose is missed and it is more than 8 hours since the scheduled time, skip that dose and take the next scheduled dose at the regular time.

    The CYP3A inhibitor contraindication during ramp-up: a clinically important interaction Sonrotoclax is metabolized by CYP3A4. Strong CYP3A inhibitors, including azole antifungals (fluconazole, voriconazole, itraconazole), certain macrolide antibiotics (clarithromycin), and HIV protease inhibitors, significantly increase sonrotoclax exposure. This dramatically increases TLS risk during the ramp-up phase when doses are already being escalated. Starting Beqalzi or increasing the dose while a patient is taking a strong CYP3A inhibitor is contraindicated. Moderate CYP3A inhibitors require dose reduction. Patients and prescribers should review all concomitant medications carefully before initiating and during the ramp-up phase. If a patient needs to restart Beqalzi after a treatment break, the full ramp-up schedule must be repeated. This is an important point for patients who interrupt treatment due to adverse events or procedures.
    🔗  Also on HED: The FDA’s Real-Time Clinical Trials Initiative: AstraZeneca’s TRAVERSE Trial Involves the Same Drug Class Our post on the FDA’s April 2026 real-time clinical trials pilot covers the TRAVERSE trial, which studies acalabrutinib + venetoclax + rituximab in treatment-naive MCL at MD Anderson and UPenn. The combination of BTK inhibition and BCL-2 inhibition in the same patient population where Beqalzi is now approved for later lines illustrates how the MCL treatment landscape is being built out.

    What This Means for Patients with Relapsed Mantle Cell Lymphoma

    Beqalzi is specifically for patients who have already received at least two prior lines of therapy including a BTK inhibitor. It is not a first-line or second-line therapy. For patients currently in earlier stages of MCL treatment, this approval does not change the immediate treatment path.

    For patients who have received both a chemoimmunotherapy regimen and a BTK inhibitor and whose disease has progressed, Beqalzi now provides an FDA-approved BCL-2 inhibitor option with a 52% response rate and a median response duration of 15.8 months in a clinical trial population that closely reflects this setting.

    Questions to discuss with your hematologist or oncologist if you or a family member is in this situation:

    • Am I eligible for Beqalzi based on my treatment history? The requirement is at least two prior lines including a BTK inhibitor, with no prior BCL-2 inhibitor.
    • What is my TLS risk profile, and what monitoring and prophylaxis will I need before and during the ramp-up?
    • Are there clinical trials of sonrotoclax in combination with other agents that might be appropriate for my specific situation?
    • Are there confirmatory trials I could participate in that would contribute to the evidence base for this drug?

    Resources for patients with mantle cell lymphoma

    For patients navigating MCL treatment decisions, the Lymphoma Research Foundation maintains patient education resources on MCL specifically, including information on clinical trial participation. The NCI’s Cancer Center directory can help identify centers with dedicated lymphoma programs and access to the newest approved therapies. For Beqalzi specifically, BeOne Medicines’ patient support program information will be available through the treating oncologist or hematologist at prescribing.

    Sources

    FDA accelerated approval announcement: FDA grants accelerated approval to sonrotoclax (Beqalzi) for relapsed or refractory mantle cell lymphoma. FDA.gov. May 13, 2026.

    AJMC coverage: Sonrotoclax Granted Accelerated Approval for R/R Mantle Cell Lymphoma. ajmc.com. May 13, 2026.

    Hematology Advisor: FDA Grants Accelerated Approval to Beqalzi for R/R Mantle Cell Lymphoma. hematologyadvisor.com. May 2026.

    OncLive: FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma. onclive.com. May 13, 2026.

    CancerNetwork: FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma. cancernetwork.com. May 2026.

    Targeted Oncology: FDA Approves Next-Gen BCL2 Inhibitor Sonrotoclax for R/R Mantle Cell Lymphoma. targetedonc.com. May 2026.

    CURE Today: FDA Approves Beqalzi for Relapsed Mantle Cell Lymphoma. curetoday.com. May 2026.

    ASCO Post: Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL. ascopost.com. May 2026.

    Oncology Nursing News: FDA Approves Sonrotoclax for R/R Mantle Cell Lymphoma. oncnursingnews.com. May 2026.

    Drugs.com drug information: Beqalzi (sonrotoclax): Uses, Dosage, Side Effects, Warnings. drugs.com.

    Trial registration: BGB-11417-201. A Study of Sonrotoclax (BGB-11417) in Participants With B-Cell Malignancies. NCT05471843. clinicaltrials.gov.

    Patient resources: Lymphoma Research Foundation: lymphoma.org; NCI Cancer Centers: cancer.gov/research/nci-role/cancer-centers

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Beqalzi is approved under the accelerated approval pathway, and continued approval may depend on confirmatory trial results. All treatment decisions for mantle cell lymphoma should be made in close consultation with a qualified hematologist or oncologist.
  • Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs.

    Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs.

    📌 The essentials On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus (insulin glargine, Sanofi) developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. It is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (2021) and Rezvoglar (2022). Interchangeable designation: pharmacists may substitute Langlara for a Lantus prescription without calling the prescriber first, subject to state pharmacy laws. Approved populations: adults and pediatric patients with type 1 diabetes, and adults with type 2 diabetes. Clinical basis: a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841 comparing insulin glargine-aldy to insulin glargine in healthy adults. Important caveat: pricing and launch date have not been publicly announced. Whether Langlara improves real-world access for patients who currently ration insulin depends almost entirely on pricing and formulary decisions not yet made.

    Approximately 8.4 million Americans require insulin to survive or to manage their diabetes. For many of them, affording that insulin is not straightforward. Lantus, the most prescribed basal insulin in the world, carries a list price of several hundred dollars per month without insurance. Published surveys estimate that 1 in 4 people with diabetes in the United States reports rationing or skipping doses because of cost.

    On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. The approval carries an interchangeable designation, meaning pharmacists may substitute it for Lantus at the counter without contacting the prescriber first, in states that permit such substitution.

    Langlara is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (insulin glargine-yfgn) in 2021 and Rezvoglar (insulin glargine-aglr) in 2022. Whether a third entry meaningfully improves access for patients depends almost entirely on pricing and formulary decisions that have not yet been publicly announced.

    What Insulin Glargine Is and Why Basal Insulin Matters

    Insulin glargine is a long-acting insulin analog engineered to provide steady, predictable background insulin coverage over approximately 24 hours. The body requires two types of insulin coverage: basal, which suppresses the liver’s continuous glucose output between meals and overnight, and bolus, which handles the glucose spike that follows eating. People with type 1 diabetes produce no insulin at all and require both. Many people with type 2 diabetes eventually require basal insulin when oral medications and lifestyle changes no longer provide adequate glycemic control.

    Insulin glargine (Lantus) was the first long-acting analog approved to replace older NPH insulin, which had a pronounced peak effect and required twice-daily dosing in many patients. Lantus’s flat, peakless 24-hour profile allowed once-daily dosing with lower rates of nocturnal hypoglycemia. Since its original approval in 2000, it became the most widely prescribed basal insulin in the world.

    Why insulin was reclassified as a biologic, and why that matters for biosimilars Until 2020, insulin in the United States was regulated as a drug under the Federal Food, Drug, and Cosmetic Act rather than as a biologic. This meant insulin could not be approved via the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), the legal framework that allows biosimilars to enter the market and compete with reference products. In March 2020, all insulin products were transitioned to biologic status under the BPCIA. This opened the regulatory pathway for true interchangeable biosimilar approvals for insulin products, with the potential for pharmacy-level substitution. Semglee became the first interchangeable insulin biosimilar in July 2021, followed by Rezvoglar, and now Langlara. The transition also means that the FDA interchangeability standard, which requires switching studies demonstrating no loss of efficacy or increase in adverse events when alternating between the biosimilar and the reference product, now applies to insulin biosimilars.

    Biosimilar Versus Interchangeable: A Distinction That Matters at the Pharmacy Counter

    Not all biosimilars are interchangeable, and the distinction has real consequences for how patients access the product.

    Biosimilar onlyInterchangeable biosimilar
    FDA standardHighly similar to reference product; no clinically meaningful differences in safety, purity, or potencyAll biosimilar standards plus: switching studies showing no greater risk than reference product when alternating
    Pharmacy substitutionCannot be substituted automatically; requires new prescription or prescriber authorization in most statesPharmacist may substitute for the reference product without calling the prescriber, subject to state law
    Patient impactAccess depends on prescriber writing specifically for the biosimilar or insurer mandating itPatient may receive the biosimilar on a Lantus prescription without any additional action from their doctor
    Langlara statusYesYes, interchangeable designation granted April 29, 2026

    The interchangeable designation requires manufacturers to conduct switching studies in which patients alternate between the biosimilar and the reference product at least three times, to confirm there is no loss of efficacy or increase in adverse events from switching. For Langlara, the approval was based on a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841, comparing insulin glargine-aldy to insulin glargine in healthy adults, along with the broader analytical and preclinical data package.

    The Insulin Glargine Landscape: Three Interchangeable Biosimilars, One Reference Product

    ProductMakerFDA approvedStatus
    Lantus (insulin glargine)Sanofi2000Reference product
    Basaglar (insulin glargine-aglr)Eli Lilly2015Biosimilar only (not interchangeable); launched 2016
    Semglee (insulin glargine-yfgn)Biocon/Viatris2021First interchangeable insulin biosimilar; launched at approximately $148 per 5-pack vs. Lantus approximately $340 to $520 per month
    Rezvoglar (insulin glargine-aglr)Eli Lilly2022Second interchangeable biosimilar; launched April 2023 at $92 per 5-pack (77% below Lantus list price)
    Langlara (insulin glargine-aldy)Lannett/Lanexa/Sunshine LakeApril 29, 2026Third interchangeable biosimilar; pricing and launch date not yet announced

    The competitive pricing history of this space is instructive. When Semglee launched as the first interchangeable biosimilar in 2021, it priced at a wholesale acquisition cost of approximately $148 per package of five prefilled pens, compared with $340 to $520 per month for Lantus without insurance. Eli Lilly’s Rezvoglar entered in April 2023 at $92 per 5-pack, setting a new low-price benchmark. Whether Langlara will compete at or below these levels has not been disclosed.

    For context on how the biosimilar market is evolving in another drug class, see our post on PONLIMSI and the crowded denosumab biosimilar landscape, where 19 FDA approvals have produced only modest savings for patients due to the same rebate dynamics described below.

    For related coverage of what is changing in the broader insulin landscape, see our post on Awiqli, the first once-weekly basal insulin approved for type 2 diabetes in 2026.

    The Access Question: Why Regulatory Approval Is Not the Same as Affordable Access

    An FDA approval of an interchangeable biosimilar is a necessary condition for improved insulin access. It is not, on its own, sufficient. The history of insulin biosimilars in the United States illustrates the gap.

    Semglee launched in 2021 with a list price meaningfully below Lantus. But list prices are not what most insured patients pay: pharmacy benefit managers (PBMs) negotiate rebates with manufacturers, and those rebate arrangements often favor the originator product on formulary even when a biosimilar carries a lower list price. The result is that biosimilar insulin market penetration in the United States has grown more slowly than in Europe, where national procurement systems and institutional substitution policies have driven biosimilar adoption rates above 90% in some countries.

    California’s CalRx Biosimilar Insulin Initiative offers a different model. As of January 1, 2026, CalRx-branded insulin glargine pens became available to California residents at $55 for a five-pack through a state partnership with Civica Rx and Biocon Biologics, regardless of insurance status. That price point, enabled by state procurement rather than commercial market dynamics, illustrates what becomes possible when the insulin access question is addressed as a public health problem rather than a market competition question.

    For Langlara specifically, Lanexa Biologics has stated its intention to pursue broad formulary placement across all commercial channels. Whether that translates to meaningful out-of-pocket savings for the 1 in 4 diabetes patients who report difficulty affording insulin will depend on the specific list price set at launch and the formulary tier negotiations that follow.

    What patients transitioning to any insulin glargine biosimilar should know No dose conversion is required when switching between interchangeable insulin glargine products. The biosimilar delivers the same clinical effect at the same dose as Lantus. Blood glucose monitoring is still recommended during any transition period, as individual insulin requirements can vary based on factors unrelated to the product switch itself. Device differences matter. Langlara is supplied as a prefilled pen. Lantus is available in both a prefilled pen and a vial. If your current regimen uses a vial and your pharmacy substitutes a prefilled pen, confirm the administration steps with your pharmacist or diabetes care team. If your pharmacist has substituted a biosimilar for Lantus, they are required by law to notify you and your prescriber of the substitution in states with such requirements. Ask your pharmacist about the specific rules in your state. If you have concerns about a substitution, you or your prescriber can request that a specific product be dispensed by noting “dispense as written” on the prescription.

    Safety Profile: Consistent With the Insulin Glargine Class

    As an interchangeable biosimilar, Langlara is expected to have the same clinical profile as Lantus. Warnings, precautions, and adverse reactions apply to the insulin glargine class as a whole.

    • Hypoglycemia: The most clinically important risk of any insulin therapy. Severe hypoglycemia can be life-threatening. Risk increases with missed meals, excessive exercise, alcohol use, renal impairment, and co-administration with other glucose-lowering agents including sulfonylureas.
    • Medication errors: Insulin concentration errors are a documented source of patient harm. Langlara is U-100 (100 units per mL). Never use U-100 insulin in a syringe designed for a different concentration. Do not mix insulin glargine with other insulins.
    • Hypokalemia: Insulin drives potassium into cells. Monitoring of potassium is important in patients at risk, including those with renal disease or on medications that lower potassium.
    • Hypersensitivity: Severe or life-threatening hypersensitivity reactions, including anaphylaxis, have been reported with insulin products. Discontinue and seek emergency care if systemic hypersensitivity occurs.
    • Thiazolidinediones (TZDs): Pioglitazone and similar drugs used alongside insulin can cause fluid retention and increase the risk of heart failure. Patients on both should be monitored for signs of fluid retention.
    • Injection site reactions: Lipodystrophy (skin thickening or pitting at injection sites) can develop with repeated injections at the same site. Rotate injection sites within the recommended areas (abdomen, thigh, deltoid).

    What This Approval Means in Practice

    Langlara’s approval adds a third interchangeable insulin glargine biosimilar to the U.S. market. The interchangeable designation is meaningful: it allows pharmacy-level substitution without a new prescription, which reduces one logistical barrier to biosimilar uptake. Whether it reduces the financial barrier depends on what Lanexa Biologics announces for pricing and formulary positioning at launch.

    For patients currently on Lantus or another insulin glargine product, the most useful resources while commercial pricing evolves are the American Diabetes Association, which maintains current guidance on insulin assistance programs and state programs, and InsulinHelp.org, a nonprofit directory of insulin access resources. The JDRF also maintains updated insulin affordability resources specifically for people with type 1 diabetes.

    For more on how biosimilar approvals interact with real-world access, and why regulatory clearance does not automatically translate to patient savings in the U.S. market, see our post on PONLIMSI and the denosumab biosimilar landscape.

    Sources

    Lannett/Lanexa/Sunshine Lake press release: Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA (insulin glargine-aldy). BioSpace. May 4, 2026.

    Drugs.com approval history: Langlara (insulin glargine-aldy) FDA Approval History. drugs.com.

    Drug Topics: FDA Approves Langlara as Interchangeable Biosimilar to Insulin Glargine. drugtopics.com. May 2026.

    Pharmacy Times: FDA Approves New Interchangeable Biosimilar of Insulin Glargine. pharmacytimes.com. May 2026.

    Endocrinology Advisor: Langlara Receives FDA Nod as Interchangeable Lantus Alternative. endocrinologyadvisor.com. May 2026.

    Contemporary Pediatrics: FDA approves interchangeable insulin glargine-aldy for type 1 and type 2 diabetes. contemporarypediatrics.com. May 2026.

    FDA prescribing information: LANGLARA (insulin glargine-aldy) Prescribing Information. BLA 761412. FDA.gov. 2026.

    Phase 1 PK/PD study registration: NCT05248841. A Study to Assess the Pharmacokinetics and Pharmacodynamics of Insulin Glargine-ALDY Versus Insulin Glargine. ClinicalTrials.gov.

    Semglee FDA approval: FDA approves Semglee, first interchangeable biosimilar insulin. FDA.gov. 2021.

    Rezvoglar FDA approval: FDA approves insulin glargine-aglr (Rezvoglar). FDA.gov. 2022.

    CalRx Biosimilar Insulin Initiative: CalRx. $55 per 5-pack prefilled pen. calrx.ca.gov. January 2026.

    Biosimilar insulin market context: Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes. PMC. doi:10.18553/jmcp.2021.21253.

    FDA interchangeable biosimilars: Biosimilar and Interchangeable Products. FDA.gov.

    FDA BPCIA framework: Biosimilar Development, Review, and Approval. FDA.gov.

    PBM market structure: Pharmacy Benefit Managers. PMC7748166.

    Patient resources: American Diabetes Association | InsulinHelp.org | JDRF insulin affordability resources | CalRx insulin program

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. All insulin therapy decisions, including switching between products, should be made in consultation with your diabetes care provider or endocrinologist.

healthevidencedigest